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PREFACE 
The Frog Embryo Teratogenesis.Assay: Xenopus is an in 
vitro bioassay designed to determine the potential 
teratogenic hazard a compound or complex mixture poses to 
developing orga11isms. Metabolism is a significant obstacle 
for most in vitro developmental toxicity assays and should 
not be overlooked ,ina proper screening test. If FETAX is 
to be routinely used for assessing potential hazard it must 
be combine with a properly validated exogenous metabolic 
activation system. Thus, this project was conducted to 
increase the overall acceptance of FETAX and an exogenous 
bioactivation system by evaluating its predictability, 
applying it to a variety of situations, and investigating 
potential short-comings of the system. By so doing, it is 
hoped that this research will spur other scientists in both 
biomedical and environmental toxicology to use FETAX 
routinely as a screen for potential developmental toxicants. 
. ' ' 
This dissertation is divided into four chapters. 
Chapter I provides background and introductory information. 
Chapters II through IV describe evaluation and application 
studies of the exogenous metabolic activation system. 
Chapter II describes the evaluation of the Aroclor 1254-
induced metabolic activation system with compounds thought 
iii 
to be either proteratogenic, bioinactivated by cytochrome P-
450, or virtually unaffected by mixed functional oxidase 
metabolism in mammalian test sy~tems. This work has been 
published in the Journal of Applied Toxicology (Volume 9, 
pages 377-388, 1989). Chapter III provides a discussion of 
the developmental toxicity of the tuberculostatic drug 
isoniazid. This section provides an explanation of why 
-,' } 
isoniazid produ9es false-positive test results with in vitro 
developmental toxicity screening ~ystems when tested without 
a suitable bioactivation syst~m. A discussion of the 
counter-productivity of Aroclor 1254..:.induced metabolic 
activation systems is also provided. Chapter III has been. 
submitted to , Teratogenesis, ca:rcinogenesis, and Mutagenesis 
and is currently being reyiewed. Chapter IV desc'ribes an 
investigation of the toxicological mechanisms of action of 
' . 
the known mammalia:ry.teratogen, diphenylhydantoin, using 
FETAX, an in vitro metabolic activ~tion system, and various 
metabolic inhibitors. Chapter IV has been accepted.for 
publication by Fundamental and Applied Toxicology. 
Several people, were· instrumental in the 'completion of 
this research project. I am indebted to all. those who 
assisted. Dr. Jack Bantle served as my major adviser. Jack 
not only provided more tha~ ~dequat~ funding for the 
completion of my research, but 'also'financially supported 
presentation'of this work at various meetings. Drs. S.L. 
"Bud" Burks, Jim Blankemeyer, and Cyril Clarke served as 
additional advisery committee members. Their help was much 
iv 
appreciated. Several others provided assistance including: 
Doug Dawson, Jim Rayburn, Donna DeYoung, Brenda James, 
Shirley Bush, P.K. Work, Bruce Vande Lune, Mendi Hull, and 
last but certainly not least Mollie Gray. Thanks are also 
due to Drs. Margaret Ewing, Karen McBee, and Larry Talent 
for their critical review of the manuscripts. 
The assistance of Dean Norman Durham and the staff of 
the University Center for Water Research (UCWR) was very 
much appreciated. The UCWR supported this research through 
a Presidential Research Fellowship as well as numerous 
grants. Reseach was also supported by the March of Dimes 
Birth Defects Foundation, the Oklahoma Center for the 
Advancement of Science and Technology (OCAST), and the u.s. 
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CHAPTER I 
INTRODUCTION 
Background -
Increasing demands for developmental toxicity 
screening necessitate the development, validation and use of 
alternative screening systems (1-10) to the traditional 
mammalian test systems. In vitro teratogenesis screening 
systems may provide a rapid, cost-effective method of 
indentifying compounds and complex environmental mixtures 
which may be potential teratogenic hazards (11). 
Alternative models may also alleviate burdens associated 
with increasing concern for animal welfare. A fundamental 
problem shared by many in vitro developmental screening 
systems is the inability to metabolize xenobiotics. This 
presents a major problem in the detection of proteratogenic 
compounds, as well as compounds inactivated by the mixed-
functional oxidase system (MFO). 
The Frog Embryo Teratogenesis Assay: Xenopus (FETAX) is 
a 96-hour static-renewal bioassay designed to screen 
potential developmental toxicants in the workplace or the 
environment (12). Since Xenopus embryos lack many metabolic 
systems including the MFO system prior to 96-hours of 
1 
development an exogenous metabolic activation system was 
developed using Aroclor 1254-induced rat liver microsomes 
( 13) • 
Objectives 
The specific objective of this dissertation research 
was to combine evaluation of theexogenous metabolic 
activation system with creative applications of this system 
using FETAX. To accomplish this objective two areas of 
investigation were emphasized: evaluation and applications. 
The evaluation process was further subdivided into 
validation studies and estimation of potential short-comings 
of the Aroclor 1254-induced m'etabolic activation system. 
'Metabolic,, Incompetence 
A recognized obstacle in most in vitro assay systems is 
the inability to biotransform compounds into active 
teratogenic species. Metabolism must not be overlooked in a 
proper screening test (11). Furthermore, compounds should 
be tested both with and without"a metabolic activating 
system, exogenous when necessary. 
Obviously, some metabolic activation systems are 
incompatible with the viability of the test. Of those tests 
supplying a source of metabolism, the Ames mutagenicity test 
(14) and a cultured whole rat embryo screen (15) employ rat 
liver S-9 supernatant. Drosophila have been successfully 
cultured with both Drosophila and rat liver S-27 and S-9 
2 
supernatant (16). In addition, cultured mouse erythrocytes 
have been used to mediate the the metabolic activation of 
cyclophosphamida_in the Saccharomyces cerevisiae 
mutagenicity test (17). 
Noshiro and Omura (18) demonstrated that Xenopus 
embryos exhibit little xenobiotic metabolism although the 
adult has limited capabilities. Therefore, through 96 h of 
development Xenopus- embryos are virtually useless for 
' ' . . 
detecting prote!atogenic compounds witho~t an exogenous 
metabolic activation system. 
Experimental Design 
Detection of Teratogenic Agents Using 
Xenopus Embryos 
The original study qn a bioassay employing Xenopus to 
detect environmental teratogens'~as performed by Greenhouse 
(19). Greenhouse used a short-term (48-hour) protocol 
exposing embryos to N-phenyl-a-napthylamine and various 
hydrazines to demonstrate the deleterious effects on 
developing embryos. Dumont et al. (12) demonstrated the 
· hazardous effects of coal-conversion, shale and oil products 
on Xenopus embryos using a 96 h exposure protocol. 
In order to measure the teratogenic potential of a 
substance, Xenopus embryos in the late blastulae stage 
were exposed to different concentrations of a toxicant. 
Mortality, malformation, and growth were measured at the end 
3 
of the 4 day test. As a measure of predicting the 
teratogenic·hazard of a given substance, a·teratogenic 
index (TI) was calculated by dividing the 96 h LC50 (median 
lethal concentration) by the EC50 (malformation) (median 
teratogenic concentration) (12). Compounds with TI values 
greater than 1.5 are considered to have strong teratogenic 
potential. Subsequently, several laboratories (10,12,20) 
have used FETAX for the screening of potential developmental 
toxicants. 
Design of Metabolic Activation 
System 
Five days prior to microsome preparation, an adult 
Sprague-Dawley (SD) co.~train male rat (200-280 g) was 
injected with 500 mgjKg,Aroclor 1254 in corn oil (21). 
·Liver was perfused with 50 ml of 1.15% KCl containing 0. 02 M 
Tris-HCl buffer, pH 7.5. ·Homogenization was performed in 
1.15% KCl containing 0.02 M Tris-HCl buffer and 0.5% bovine 
serum albumin (BSA). The homogenate was centrifuged 
successively at 600 and 9000 x g avg. The crude S-9 
supernatant was further purified by two additional 
ultracentrifugation steps at 102 ,·ooo x g avg. The 
microsomal pellet was then resuspended in 0.05 M Tris-HCl 
bu~fer, pH 7.5, put into' 1 ml aliquots, and immediately 
frozen in liquid nitrogen (22). Protein was determined by 
the method of Bradford (23) (BioRad, Richmond·, CA). P-450 
activity was inferred py the measurement of formaldehyde 
4 
generated from the N-demethylation of aminopyrine by the 
method of Nash (24). Assay conditions were described by 
Lucier et al. (25). Several aliquots of microsomes were 
chemically~ reduced with dithionite and pretreated with 
carbon monoxide (CO) to selectively inactivate P-450 
activity (26). 
Animal Care and Bree~ing 
Xenopus adult care, breeding, and embryo collection was 
performed according to Courchesne and Bantle (20). 
Assay Protocol 
For each separate cl~tch of embryos, four sets of 20 are 
placed in 60 mm covered plastic Petri dishes containing 
FETAX solution, a reconstituted· water media (27), and 100 
U/ml penicillin-100 ugjml streptomycin in 8 ml of total 
solution. These were designated FETAX~controls. Treatments 
were performed in duplicate'with 20 embryos per dish. Each 
test dish received microsomal protein, NADPH generating 
system, 100 U/ml penicillin-100' ugjml streptomycin, and 
various concentrations of toxicant. The NADPH generating 
system consisted of 3.5 mM glucose 6~phosphate, 0.31 Ujml 
glucose 6-phosphate dehydrogenase, 0.1 mM NADP, and 0.007 mM 
NADPH. Metabolic activation system, activated 
cyclophosphamide [positive control], and co-gassed 
microsomes and toxicant [negative control] were prepared in 
a similar manner. All dish~s contained 8 ml of the 
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appropriate solutions, which were previously diluted from 
stocks prepared in FETAX solution. All solutions were 
removed every 24 h of the four d test and fresh solutions 
added in a static-renewal fashion. 
Data Collection and Analysis 
Dead embryos were removed every 24 h and the number 
recorded. Death at 24 and 48 h was ascertained by embryo 
skin pigmentation, structural integrity, and irritability. 
At 72 and 96 h the lack of a heart beat was an unambiguous 
sign of death in the transparent embryo. Surviving larvae 
were fixed in 0.6% formalin, pH 7.0. The number of live-
malformed embryos and the stage of development according to 
Nieuwkoop and Faber (28) were determined. Dose-response 
bioassays evaluated according to Litchfield-Wilcoxon (29) 
were used to determine the 96 h LC50 and EC50 
(malformation) . The 96 h LC50 was divided by the EC50 
(malformation) yielding a teratogenic index (TI) which has 
proven useful in assessing teratogenic hazard (13,20,27,30). 
Head-tail length was measured using a Radio Shack digitizer 
and model 16 microcomputer. 
Approach 
Evaluation 
Validation. Validation is the process of selecting a 
number of compounds which have well characterized mammalian 
6 
teratogenic potential in vivo, testing them in the model 
system, and comparing the results (31). Thus, evaluation of 
the system was needed to demonstrate that the metabolic 
activation system was adequately predicting the potential 
teratogenic hazard of chemicals tested in FETAX. As many as 
50 compounds of varying teratogenic potency may need to be 
tested to fully validate the assay (11). In this portion of 
the study, testing was completed within time and cost 
restraints to evaluate the predictability of FETAX and the 
Aroclor-induced exogenous metabolic activation system. 
Three compounds suspected to be proteratogenic in mammalian 
test systems, one compound unaffected by mixed-functional 
oxidase metabolism, and one compound inactivated by 
cytochrome P-450 were selected from several published lists. 
Ideally, evaluation of this metabolic activation system 
should determine whether or not it is the system of choice 
for FETAX. 
Short-Comings. Aroclor 1254 induces P-450 isozymes 
characteristic of the two prototype inducers 3-
methylcholanthrene (3-MC) and phenobarbital (PB) (32). 
Thus, Aroclor 1254-induced microsomes are quite effective in 
metabolizing a diverse array of xenobiotics. Interestingly, 
several investigators (33,34) have found decreased levels of 
other putative P-450 isozymes, including the pyrozole-
inducible P-450j. The Aroclor 1254-induced system should be 
highly effective for investigating the developmental 
toxicity of compounds metabolized by 3-MC or PB inducible 
7 
isozymes. However, compounds metabolized by isozymes 
repressed by Aroclor 1254 would have a greater chance of 
being falsely scored, thus causing Aroclor 1254-induction to 
be counter-productive. ·In this study, attempts were made to 
determine the magnitude of this problem using the tuberculo-
static drug isoniazid and metabolic activation system 
induced by different chemical agents., Isoniazid was found 
previously to be metabolized by P-450j (35). The specific 
aim of this portion of the research was to determine whether 
or not a potential problem exists and develop modifications 
if needed. Ultimately, this would improve the predictive 
value of the metabolic activation system and should aid in 
overall acceptance of FETAX by future investigators. 
Applications. In order for FETAX to gain acceptance 
as an in vitro developmental toxicity screening assay a 
variety of practical applications and overall versatility 
must be demonstrated. Since Xenopus embryos lack MFO 
activity prior to 96-h of development, testing with and 
without an exogenous metabolic activation system provides a 
means of assessing the role MFO metabolism plays in the 
potential developmental toxicity of a compound. Evaluating 
the potential teratogenicity of both parent compound and 
metabolites with the inclusion of a bioactivation system 
allows for a more accurate account of what may be occurring 
in the mammal in vivo. By selectively inhibiting different 
fractions of cytochrome P-450 (P-450) isozymes, as well as, 
epoxide hydrolase with known'inh,ibitors this study helped to 
8 
demonstrate that FETAX could be used to investigate 
toxicological mechanisms of action. Occassionally, 
mammalian test systems fail to provide an adequate 
explanation of toxicological mechanisms of action of 
teratogenesl~, as is the case with diphenylhydantoin. 
Although FETAX can not pharmacologically represent the 
I 
fetal-maternal system, it was hoped that the study 
would demonstrate the utility of FETAX for studying 
toxicological mechanisms in vitro. 
Without the ability to metabolize xenobiotics, it is 
doubtful that in vitro tests such as FETAX would be 
suitable for screeing human developmental toxicants. 
Hopefully, the results of previously mentioned studies will 
suggest that FETAX is a~le to overcome the obstacle of 
metabolic incompetence. By extending this research beyond 
test compound validation, a greater contribution was made 
toward the primary goal 'Of increasing the acceptance of FETAX 
as a screen of developmental toxicants. 
Literat;:ureReview 
In Vivo Teratogenicity Testing 
Multigeneration Studies. In multigeneration tests, 
animals are continuously expose'd, to a test agent in the food 
or water for a period of three generations (see 36 for 
review) . This protocol was primarily developed to assess 
the developmental toxicity of chemicals that are likely to 
9 
bioaccumulate with long-term exposure, such as pesticides. 
Exposure generally begins shortly after weaning. Upon 
reaching reproductive maturity, animals are mated to produce 
the F1 generation. F1 offspring are then selected to 
produce the F2 generation, and the F2 individuals to produce 
the F3 offspring which are, subsequently killed and examined 
at weaning. The same treatment is administered to each 
successive generation. Typically, three treatment groups 
and one control group are utilized, with a minimum of 20 
pregnant females p~r group per generation. Use of rodent 
species as test. organisms for multigeneration tests (F3 ) 
allows completion of the study within twenty months. 
Fertility, litter size, sex ratio, neonatal viability, and 
fetal growth endpoints are commonly used to assess the 
effects of the compound on reproductive performance. 
Short-Term Techniques. Methods of evaluating the 
effects of short-term exposure may be divided into three-
segment single generation studies (see 37-39 for review) . 
Phase I tests examine effects on fertility and general 
reproductive performance. Phase II.studies, the most 
commonly employed protocol, evaluates developmental 
toxicity. Phase III tests provide a method of evaluating 
peri- and postnatal effec~s. 
Phase I tests consist of treatment of 'male and female 
rodents for approximately 70 and 14 days, respectively. 
Female exposure occurs during mating, pregnancy and 
lactation. Half of the dams are killed at mid-pregnancy and 
10 
the uterine contents examined for pre- and postimplantation 
embryo death. The remaining females are-allowed to deliver 
and nurse their brood. The offspring are subsequently 
killed and autopsied for the presence of terata. 
Segment II studies involve treatmen~ o~ a pregnant 
females during critical periods of organogenesis. Females 
are killed and'fetuses removed one ~ay prior to parturition. 
Early embryo or lat~ fetal death, abnormal development, and 
fetal body weight endpoints are then used to assess 
potential developmental toxicity. 
Pregnant females are exposed to potential developmental 
toxicants during the final third of ge~tation and through 
the weaning process in Phase III tests (39). The ultimate 
objective of these studies are to provide information 
concerning the effeqts on·late fetal development, labor and 
delivery, lactation, and neonatal viability/growth. 
Today there is grqwing concern over the adequacy and 
practicality of these metho~s for evaluating teratogenicity 
in vivo, since they were developed in response to the 
thalidomide controyersy nearly twenty years ago. 
Several modifications have been proposed for both the 
multigeneration and short-term segment tests, as well as, 
provisions for the'inclusion ~f cost- and time-effective in 
vitro teratogenesis screening assays ·(40). 
In Vitro Teratogenicity Testing 
Measurement of Teratogenic Potential. It has become 
11 
recently a~parent that the current in vivo test procedures 
are overburdened by the large number of compounds requiring 
testing. Such a predicament has given rise to the 
development of short-term teratogenicity screens. To be 
successful,~ short-term in vitro screens must mimic the 
widely accepted in vivo mammalian developmental toxicity 
' ' 
tests. However, until recently methods for validating in 
vitro systems were undefined~ Obviously several questions 
must be considered (see 11 for a review). First, what is an 
acceptable measure of teratogenic potential for in vitro 
test systems? Obviously, an ~cceptable measure of 
teratogenic potential in vitro is an endpoint that would 
predict findings of generally,~ccepted evaluations of 
teratogenic potential in vivo. 
Second, should these endpoints be related to 
embryogenic events that occur in the intact mammalian 
system? In this case., the endpoints need not necessarily be 
related to embryogenic events, although an ontogenic system 
is desirable. Eventually all in vitro screens should 
predict human teratogenicity. The wide variety· of in vitro 
developmental toxicity screen~ and the equally large number 
of endpoints used to assess potential risk makes evaluation 
difficult. Fo~ example, cell culture sy.stems measure 
endpoints far removed from malformation and functional 
deformities. Rather, it measures an event that may or may 
not be relevant to the production of malformations. 
Approaches. If a single test is to be used as a sole 
12 
indicator of teratogenic risk, the degree of 
developmental relevance to mammals must be great. Of those 
tests which bear little-relevance to ontogeny, a batte~y of 
short-term assays are generally performed to form a 
composite answer~ The ,battery approach is considered 
superior to the tier strategy ( 41) • ·In the tier system, 
compounds i~it~ally are tested ~ith inexpensi~e short-term 
tests. Those chemicals which test positive are then 
subjected to more rigorqus testing. Since false negatives 
may occur during the initial screening, the possibility that 
a t~ratogen will evade detection is greater. 
Assay Validation. In order to establish in vitro 
systems as an acceptable screening process, extensive vali-
dation-must be performed. Generally com~ounds should be 
selected on the basis of their in vivo teratogenic activity 
from a list of agent~ selected by a panel of experienced 
investigators in the areas of teratology, pharmacokinetics, 
metabolism, and chemical classification. Validation in this 
manner facilitates interlaboratory comparisons. An 
overabudance.of false-p~s~tiv~ and riegative.test results 
detract from the validity of the test, depending on its use 
as part of a test battery or a s'ingle'test, and its level in 
the overall toxicity assessment ~rocess. 
Performance and Developmental 
Relevance of FETAX 
Test performance and developmental relevance make FETAX 
13 
an attractive in vitro teratogenesis bioassay. Of 32 
compounds tested with FETAX, 85 percent were similar to 
mammalian studies- {42-43). Sabourin and Falk (44) have 
recently found that the total mammalian malformation (e.g.,· 
skeletal, visceral, nervous, etc.) caused by 17 teratogens 
were matched in Xenopus in 24/~7 {65%) of the cases. The 
correlation between laboratories using FETAX indicates-much 
promise for the assay as well. Courchesne and Bantle {20) 
found the teratogenic index of hydroxyurea to be 4.3 which 
is very similar to 4.5 obtaine~ by Sabourin et al. {10). 
However, this was not always the situation, as was the case 
with 5-fluorouracil which tested strongly teratogenic in the 
laboratories of both; ,Bantle and-Sabourin, but the 
teratogenic index v:.aried. significantly. FETAX was found to 
be the most appropriate assay when compared to the Planaria 
' (1) and the Hydra system {6). These results may be 
attributed to the multiple enqpoints of the frog assay as 
well as its higher phylogenetic position. Dumont et al. 
{12) found meclizine induced hydrocephalia in both frogs and 
mammals. Cogrchesne and Bantle· {20) found 'that several 
genotoxic compourids'caused the same-general malformations in 
both Xenopus and rodent embryos. In addition, ·anomalies 
produced by ethanol, caffeine, and 5-fluorouracil exposure 
were similar to those recorded in mammalian studies (27). 
Teratogenic Assessment In Vivo 
Assessment of teratogenic hazard in vivo centers 
14 
primarily around three endpoints: embryolethality, 
malformation~ and growth inhibition (40). The relationship 
between these endpoints is extremely complex and typically 
varies with the type of agent tested (45). Obviously, 
different agents produce myriad of reponses, however, 
several patterns are characteristic of levels of teratogenic 
hazard. 
Patterns of Response. Some developmental toxicants may 
induce abnormal development at doses which do.not cause 
embryolethality. Increasing doses beyond that which 
malforms the entire litter may induce embryolethality but is 
often in conjucti~n wit~ severe maternal toxicity. With 
such compounds, malformation is the most sensitive endpoint 
as terata is induced at qoses below that which retards 
growth. This pattern of response although rare, is 
indicative of an agent with an extremely high teratogenic 
potential. 
A much more common response involves embyolethality, 
malformation, and fetal growth inhibition. Exposure within 
an embryotoxic range may produce a combination of resorbed, 
deformed, stunted, and normal fetuses within a given litter. 
With this response pattern, a compound with high teratogenic 
potential may induce anomalies at lower doses. However, as 
the embryotoxic· dose increases, embryolethality predominates 
as the major response. Agents with significant teratogenic 
potential would have malformation dose-response curves 
displaced to the left from the mortality curves at low 
15 
embryotoxic doses, but overlapping curves at higher doses. 
Compounds which are mainly embryolethal would display a 
converse dose-response relationship with the-mortality curve 
displaced to the left. Typically, with these type of agents 
growth is the most sensitive endpoint. The majority of 
compounds producing such a response pattern po~e moderate 
teratogenic hazard to developing organisms. 
The third response involve~ only growth inhibition and 
embryolethality. Again, growth is generally the most 
sensitive endpoint. Agents producing this type of dose-
, 
response pattern would possess l,o~ teratogenic potential. 
However, only intermediate doses within the range of 
embryolethality and growth re~ardation may determine whether 
teratogenicity has been masked by lethality. 
Teratogenic Assessment with FETAX 
The teratogenic potential o~ chemicals assayed with 
FETAX is assessed based on TI values, growth endpoints, and 
the types and severity of induced malformations. Generally, 
TI values--<1.5 indicate low teratogenic pote~tial as there 
is little or no-separation between concentrations which 
induce malformations, but cause no embryolethality, and 
concentration which are lethal. Greater TI values signify 
., -
an increased potential for teratogenesis,' as there is a 
greater chance for the embryos to be malformed in the 
absence of significant embryolethality (30). Since an adult 
to developmental (A/D) ratio (46) is not practicable with 
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FETAX, types and severity of malformations are also 
considered in test evaluations such that compounds with TI 
values <1.5 producing severe malformations in major organ 
systems may still be considered to pose a developmental 
hazard, i.e., as potent embryotoxins (27). The utility of 
the TI to evaluate potential teratogenic hazard will only 
become clear after a large data base is devel~ped. using 
FETAX. 
The minimum concentration to inhibit growth (MCIG) 
expressed as a percent of the compound LC50 is also useful 
in assessing developmental toxicity. Typically, the MCIG of 
compounds posing a strong developmental hazard will be <30% 
of the compound LC50 (27,30). 
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ABSTRACT 
The potential teratogenic hazard of five compounds was 
evaluated using the Frog Embryo Teratogenesis Assay-Xenopus 
(FETAX) and' a metabolic activation system. Embryos of the 
South African clawed frog, Xenopus laevis were exposed to 
three compounds suspec~ed to be proteratogenic i:r:1 mammalian 
test systems, [2-acetylaminofluorene (2-AAF), rifampicin 
(RA), and benzo(a)pyrene (BP)] for 96 h. One compound 
unaffected by mixed-functional oxidase (MFO) metabolism, 
znso4 (Zn) and one compound thought to be inactivated by 
cytochrome P-450, cytochalasin D (CD) were also tested. Two 
separate static renewal'tests were conducted with and 
without the-presence of an exogenous metabolic activation 
system (MAS). The metabolic activation system consisted of 
' Aroclor 1254-induced rat liver microsomes. The teratogenic 
potential of each compound and the effects of metabolic 
activation were based on ter~togenic indices [TI=96 h 
LC50/96 h EC50 (malformation)], types and severity of 
malformation, and effects on embryo growth. Metabolic· 
' ' 
activation increased the potential teratogenic hazard of 2-
AAF, RA, and BP by TI factors of 1.3, 2.8, and 6.8, 
respectively. The teratogenic potential of Zn was virtually 
unaffected by the MAS. The MAS significantly reduced the 
teratogenic potential of CD by a TI factor of 2.7. These 
results demonstrate the utility and importance of a MAS for 
in vitro developmental toxicity screens such as FETAX. 
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Consistent use of a MAS with FETAX should reduce the number 
of potential false positive and false negative test results. 
KEY WORDS: FETAX, developmental toxicity, 2-acetyl-
aminofluorene, rifampicin, benzo(a)pyrene, zinc, 
cytochalasin D. 
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INTRODUCTION 
Increasing,demands,for developmental toxicity screening 
necessitate the development, validation, and use of 
alternative screening systems to the traditional mammalian 
test systems1 • , In vitro teratogenesis screening systems may 
proyide a rapid, cost:-effective method of determining 1 
compounds and complex mixtures that may be potential 
teratogenic hazards. A fundamental problem shared by many 
in vitro developmental toxicity ~creening systems is the, 
inability to metabolize xenobiot'ics2 • This presents a major 
obstacle in the det~ctiori of proteratogens, as well as 
teratogens inactivated by the mixed-functional oxidase (MFO) 
system. 
The Frog Embryo Te~atogenesis Assay: Xenopus (FETAX) is 
' 
a 96-h static renewal bioassay designed to screen potential 
developmental toxicants3 . Since Xenopus embryos lack, many 
metabolic enzyme systems through the first 96 h of 
development, an exogenous metabolic activation system was 
developed for FETAX using Aroclo~ 1254-induced rat liver 
microsomes4 • -In'· this study, the proteratogen-
cyclophosphamide (CP) was successfully biotransformed to its 
teratogenic metabolites. ~ecently, the developmental 
toxicity of nicotine and a p~imary metabolite cotinine on 
Xenopus embryos was evaluated using this MAS 5 • 
Bioactivation greatly reduced the teratogenicity and growth 
inhibiting effects of nicotine. 
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. ' 
This report describes the evaluation of the developmental 
toxicity of three compounds suspected to be proteratogenic, 
2-acetylamino-fluorene (2-AAF), rifampicin (RA), and 
benzo(a) pyrene (BP); one compound unaffected by MFO 
metabolism, ZnS04 (Zn) ; and one compound believed to be 
m~tabolically inactivated, cytochalasin D (CD). The results 
demonstrate the importance of a successful MAS for in vitro 
teratogenesis screening systems, such as FETAX, as well as 
the utility of these syptems in evaluating the role MFO 
metabolism plays in teratogenesis. 
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EXPERIMENTAL 
Chemicals and Biochemicals 
All chemicals used in rat liver microsome preparation, 
test compounds, and dimethylsulfoxide (DMSO) were purchased 
from Sigma (St. Louis, MO) . Aroclor 1254 was obtained from 
Monsanto Corporation (St. Louis, MO) 
Microsome Preparation 
Aroclor 1254-induced rat liver microsomes were prepared 
as previously described4 . Adult male Sprague-Dawley C/D 
strain rats (200-300. g) were injected with 500 mgjKg Aroclor 
1254 in corn oil five days prior to microsome preparation6 . 
Following cervical dislocation, the liver was exposed and 
perfused with 50 ml 0.02 M Tris-HCl buffer containing 1.15% 
KCl, pH 7.5. The liver was homogenized in 1.15% KCl-0.02 M 
Tris-HCl buffer containing 0.5% bovine serum albumin, pH 
7.5. The homogenate was then centrifuged successively at 
600 and 9,000 x g ave. The. S-9 supernatant was further 
purified by two additional ultracentrifugation steps at 
102,000 x g ave. The microsomal pellet was resuspended in 
0.05 M Tris-HCl, pH 7.5,'put into 1.5 ml aliquots, and 
immediately frozen in liquid nitrogen7 . Protein content was 
determined by the method of Bradford8 • cytochrome P-450 (P-
450) activity was inferred by the measurement of 
formaldehyde generated from the N-demethylation of 
aminopyrine (APD) 9 under standard assay conditions 
previously established10 . Several aliquots of microsomes 
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were chemically reduced with dithionite and pretreated with 
carbon monoxide (CO-MAS) to selectively inactivate P-450 
activity11 • 
Animal Care and Breeding 
Xenopus adult care, breeding, and embryo collection 
were performed according to Courchesne and Bantle12 • 
Assay Procedure 
Initial tests ·were conducted to determine the maximum 
amount of DMSO which could be used as diluent and the effect 
it had on P-450 activity. For unactivated tests, groups of 
20 embryos were placed in 60 mm'covered plastic Petri dishes 
with varying·concentrations of the appropriate test 
compound. 2-AAF, RA, BP, and CD stock solutions were 
prepared by dissolving in 1% :(vjv) DMSO diluted in FETAX 
' 
solution, a reconstituted water medium13 • znso4 was 
dissolved in_ appropriate volumes of FETAX solution. For 
each compound 8 to 13 concentrations were tested with 
replicates. Four separate' dishes of 20 embryos were exposed 
to FETAX solution '(designated FETAX solution controls) . 
Forty embryos,, ·20 pe'r dish, were exposed to 1%' DMSO in FETAX 
solution and served as solvent controls. Each treatment 
contained a total of 8 ml of solution. 
Stock Zn concentrations were determined by atomic 
absorption analysis. To facilitate the comparison of tests 
within this study and previous work with zn14 , the 
concentration of each test dilution was normalized to 100 
ugjml hardness (as caco3)15,16. 
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The metabolically activated tests were also conducted 
in duplicate with 20 embryos per dish. Stock solutions were 
prepared as. described for the unactivated tests. Each 
activated treatment received o .,04 U APD activity (units 
expressed as uM formaldehyde/min), an NADPH generating 
system, and 100 U/ml penicillin-100 ugjml streptomycin. The 
NADPH generating system consisted of 3.5 mM glucose-6-
phosphate, 0.31 IU/ml glucose-6-phosphate dehydrogenase, 0.1 
mM NADP, and 7 .,0 uM NADPH. Each dish received no more than 
0.06 mgjml microsomal protein4 . Controls for FETAX solution, 
DMSO, MAS, DMSO +MAS, CP (FETAX reference proteratogen) 5 , 
CO-MAS+ toxicant (negative control), and unactivated 
toxicant were also run with each test. 
For each compound, one range-finder and two separate 
definitive tests were conducted with and without the MAS. 
I 
The pH of all stock sdlutions was maintained between 7.0 and 
8.0. Embryos were cult~red at 23°C throughout the test. 
All solutions were removed every 24 h of the 4-d test and 
fresh solutions were added. Dead embryos were removed at 
this time. After 96 h of exposure, surviving embryos were 
fixed in 0. 7% formalin, pH 7 .-0. The number of live 
malformed embryos and,. the stage of development17 were 
determined using a dissecting microscope. 
Data Analysis 
Litchfield-Wilcoxon probit analysis was used to 
ascertain the 96-h LC50, the median lethal concentration and 
the 96-h EC50, the concentration inducing gross terata in 50 
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percent of the surviving embryos18 • The 95 percent 
confidence limits were calculated as well. A Teratogenic 
Index (TI) which has proven useful in assessing teratogenic 
hazard3-S,l3 , 19 was determined by dividing the 96-h LCSO by 
the 96-h ECSO (malformation). Head-tail length (growth) was 
measured using a Radio Shack digitizer and a model 16 
microcomputer. 
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RESULTS 
Control Experiments 
Preliminary tests indicated that upon exposure to 1% 
(vjv) DMSO, microsomal APD activity was 0.05 Ujmg protein + 
0.01 (n=6), which was not significantly different from FETAX 
solution controls, 0.05 ,Ujmg protein+ 0.03 (n=6) (grouped 
t-test, p<0.05) .. The lowest observable effect concentration 
(LOEC) (Dunnett,'s test) and the,minimum concentration to 
inhibit growth (MCIG) (grouped t-test, p<0.05) for the 
embryos exposed to DMSO for 96 h were 1.4 and 1.2% (vjv), 
respectively. 
In all tests conducted, FETAX solution control embryo 
mortality and malformation rates were less than 6%. 
Mortality and malformation rates in the MAS and DMSO 
controls were below 6 and 7%, respectivley. Mortality and 
malformation rates in control embryos exposed to the MAS and 
DMSO simultaneously were 15% or less. At least 90% of the 
embryos exposed to 4.0 mgjml activated CP, di~d before 96 h. 
Survivors were severely malformed. Control embryos exposed 
to 4.0 mgjml unactivated CP exhibited' malformation and 
mortality rates less·than or equal to 15%. 
2-Acetylaminofluorene 
Results from,tests with 2-AAF ar~ presented in Table I. 
The mean unactivated 96-h LC50 was 88.5 ugjml. The mean 96-
h EC50 (malformation) was 7.2 ugjml, yielding a TI of 12.4. 
Metabolic activation reduced the 96-h LC50 at least 1.9 fold 
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to approximately 42.5 ugjml. Activation reduced the 96-h 
EC50 (malformation) to approximately 2.6 ugjml (2.7 fold). 
The average TI value was 16.7. Malformations induced by 
unactivated 2-AAF included improper gut coiling and 
pericardial edema at concentrations greater than 6 ugjml. 
At concentrations greater than 10 ugjml severe gut 
/ 
malformations, ophthalmic edema, and craniofacial 
abnormalities were also observed. Gut miscoiling, edema of 
the pericardium, ophthalmic region, and dorsal fin, and 
severe microophthalmia were elicited by activated 2-AAF at 
concentrations greater than 1.0 ugjml. Concentrations 
greater than 10 ugjml bioactivated 2-AAF produced severe 
skeletal kinking, malformations of the mouth, and 
microencephaly. The effects of unactivated and bioactivated 
2-AAF on embryo growth is illustrated in Fig. 1. Exposure 
to metabolically activated 2-AAF had a greater growth 
inhibiting effect than did exposure to unactivated 2-AAF. 
Growth reduction as the result of 2-AAF bioactivation was 
also greater than the additive growth inhibition caused by 
the MAS + DMSO and unactivated 2-AAF treatments. Embryos 
exposed to CO-MAS and 85 ugjml 2-AAF were 75.5% of FETAX 
solution control growth. 
Rifampicin 
Unactivated RA was not developmentally toxic at the 
limit of solubility in 1% (vjv) DMSO, thus the 96-h LC50 and 
EC50 (malformation) values are expressed as >2.0 mgjml 
(Table II). Bioactivation decreased the 96-h LC50 to 
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approximately 1.4 mgjml. The mean 96-h EC50 (malformation) 
for bioactivated rifampicin was 0.5 mgjml and the TI was 
2.8. Activated RA concentrations greater than 50 ugjml 
caused miscoiling of the gut, craniofacial deformities, and 
microophthalmia. Severe microencephaly, ophthalmic and 
pericardial edema, and skeletal kinking were produced in 
concentrations above 1.0 mgjml. The effect of metabolic 
activation of RA on embryo growth is presented in Figure 2. 
Activated RA concentrations less'than 1 mgjml caused slight 
growth inhibition. However, the reductions may have been 
caused by the sum of the actions of the MAS + DMSO and 
unactivated RA treatments. Unactivated RA concentrations 
greater than 1 mgjml caused increased embryo growth compared 
to FETAX solution controls, whereas activated concentration 
greater than 1.0 mgjml caused marked growth reduction. 
Embryonic growth in the FETAX solution controls and the co-
MAS + 2.0 mgjml RA treatment was nearly identical. 
Benzo(a)pyrene 
Results from tests with BP are shown in Table III. The 
96-h LC50 for both unactivated and metabolically activated 
BP is expressed as greater than 10 ugjml since the median 
lethal concentration exceeded the limit of solubility in 1% 
(vjv) DMSO. The 96-h EC50 (malformation) for unactivated BP 
was about 11 ugjml. Bioactivation reduced the 96-h EC50 
(malformation) approximately 6.7 fold to 1.7 ugjml. The TI 
increased at least 5.6 fold upon activation. At 
concentrations greater than 2.5 ugjml, unactivated BP 
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elicited moderate gut malformations while concentrations 
greater·than 7.5 ugjml produced severe gut abnormalities and 
malformations of the mouth. Bioactivation induced 
ophthalmic edema, severe gut miscoiling, and mouth 
malformation at concentrations greater than 0.5 ugjml. In 
addition, microencephaly, sever~ ~ye malformations, and 
skeletal kinking were observed above' 5 ugjml activated BP. 
The effect of bioactivated BP, on embryo growth is shown in 
Fig 3. Activated. BP concent.rat;ior1s· greater than 
approximately 5 ugjml caused greater growth reduction than 
could be explained by the additive effect of the MAS + DMSO 
and unactivated BP.treatments._ ~mnryos exposed to 10 ugjml 
BP and CO-MAS were 87% of FETAX solution control growth. 
In tests without the MAS, the average normalized 96- h 
LC50 was 34.4 ugjml (Table IV). The 96-h EC50 
' c 
- > (malformation) was aproximatel'y 2.7 ugjml in tests without 
the MAS. In tests with.the MAS the mean 96-h LC50 was 36.7 
ugjml. The activate~ LC50 values standardized per ug of 
microsomal prot~in was approximately 1.6 ug Znjug protein. 
With the MAS the 96- h EC50 (malformation) was approximately 
2.9 ugjml. The TI values for unactivated Zn and Zn-MAS 
experiments were 13.3 and 12.7, respectively. Embryos 
exposed to Zn alone at concentrations above 1.5 ugjml caused 
mild gut malformations and pericardia! edema. Above 4.0 
ugjml, Zn induced severe edema of the pericardium and eye, 
gut miscoiling, and head and mouth malformations. Higher 
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concentrations caused severe skeletal kinking, 
microophthalmia, microencephaly, and craniofacial 
malformations, as well. Zn-MAS exposure produced similar 
malformations to those induced by the unactivated 
treatments. The severity of the gut miscoiling and edema 
was slightly greater at the lower concentrations (<4.0 
ugjml) when cultured with the MAS. At higher concentrations 
(>5.0 ugjml) skeletal kinking was observed less and was 
generally less severe than that produced in the unactivated 
treatments. The effect of Zn on embryo growth is shown in 
Fig. 4. Addition of the MAS had little effect on the embryo 
growth inhibiting potential of Zn. Embryos exposed to 85 
ugjml Zn (30.5-36.3 ugjml normalized) were 81.7% of FETAX 
solution control growth. 
Cytochalsin .Q 
Table V shows the results of tests conducted with CD. 
The mean 96-h LC50 for unactivated CD experiments was 450 
ngjml. The unactivated 96-h EC50 (malformation) was 
approximately 100 ngjml. In tests conducted with the MAS, 
the 96-h LC50 averaged 800 ngjml. The bioinactivated 96-h 
EC50 (malformation) was approximately 600 ngjml. The TI for 
unactivated CD was approximately 3.9 whereas the TI for 
bioinactivated CD was about 1.5. Unactivated CD 
concentrations greater than 50 ngjml induced severe 
impairment of eye formation, gut miscoiling, and 
craniofacial malformations. At concentrations greater than 
75 ngjml, microencephaly, muscular kinking, and skeletal 
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defects were observed. In tests with the MAS, severe 
miscoiling of the gut, pericardial edema, and mouth 
malformations were induced at concentrations greater than 
250 ngjml. Additional anomalies found above 900 ngjml were 
skeletal kinking, moderate cranio£acial malformations, and 
microencephaly. The effect of me~abol·ic inactivation of CD 
on embryo growth is pres~nted in Fig. 5. Addition of the 
MAS increased embryo growth compared to embryos exposed to 
CD alone. Emoryos exposed to CD and the CO-MAS were 87.1% 
of FETAX solution control growth. 
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DISCUSSION 
Results obtained in this study suggest the importance 
of metabolism in in vitro teratogenesis screening. 
-
Metabolic activation increased the developmental toxicity of 
2-AAF, RA, and B~; reduced the effect of CD; and had no 
significant- eff.ect on Zn. Generally, in FETAX, 'TI values 
less than 1.5 indicate low teratogenic potential whereas 
greater values signify an increase in the potential 
hazard4 ' 5 ' 19 • However, types and severity of malformations, 
growth inhibition, and results w~th CO-MAS are also 
considered. Some compounds with TI values less than 1.5 
produce severe malformations of major organ systems. These 
compounds may still -pose a hazard for the developing embryo 
(possibly as an embryo toxin). CO-MAS controls provide 
needed information in as.sessing the role of P-450 mediated 
metabolism in teratogenesis·. 
Bioactivation increased the TI of 2-AAF 1.3 fold from 
,, ' 
approximately 12.4 to 16.7. Even without activation 2-AAF 
is a significant teratogenic hazard in FETAX. several 
additional factors suggest. the importance of 
biotransformation in 2-AAF teratogenesis. First, activated 
2-AAF induced different types of t~rata with greater 
severity than unactivat~d 2-AAF produced. Second, embryos 
exposed to 2-AAF and the CO-MAS exhibited similar 
malformation responses including growth reduction to embryos 
exposed to unactivated 2-AAF. Metabolic activation of 2-AAF 
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primarily caused severe malformations of the brain, eye, and 
skeletal system in Xenopus. These malformations were not 
observed in unactivated treatments. Activation also caused 
a slight decrease in embryo growth and was not as marked as 
rates for RA and BP. These anomalies are simiiar to those 
found in in vivo and in vitro mammalian teratogenesis test 
systems. Izumi29 produced primarily skeletal' malformations 
by administering 2-AAF to mice between the 8th and 15th day 
of gestation. Faustman-Watts et a1.?i exposed cultured 
whole-rat embryos to 2-AAF, activated 2-AAF, and two 
metabolites N-hydroxy-2-acetylaminofluorene (N-OH-AAF) and 
N-acetoxy-2-acetylaminofluorene (N-AAAF). No malformations 
and minimal decreases in viability and growth wer~ observed 
with unactivated 2-AAF at'concentrations up to 75 ugjml. 
Concentrations above 60 ',ugjml bioactivated 2-AAF caused a 
decrease in embryo viability, i?complete closure of the 
neural tube, and a decrease in embryo growth. In the 
present study, the concentration of unactivated 2-AAF 
required to malform all Xenopus embryos was 7.5 times 
greater than activated 2':"'AAF. Thus, ·it m,ay be possible that 
concentrations greater than 75 ugjml unactivated 2-AAF were 
required to elicit,malformati!)ns in cultured rat embryos. 
These concentrations were not tested, however. N-OH-AAF and 
N-AAAF produced ventrolateral protrusion and hypoplasia of 
the prosencephalon. Although ventrolateral protrusion of 
the brain was not observed, hypoplasia of the prosencephalon 
appears to be similar to microencephaly detected with 
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Xenopus. 
Bioactivation increased the teratogenic hazard of RA as 
indicated by the rise in TI. Unactivated RA was not 
developmentally toxic at concentrations"up to 2 mgjml. In 
addition, embryos exposed to high concentrations of 
unactivated RA grew to lengths greater than that of the 
FETAX solution controls. This response may be the result of 
hormesis andjor sterilization of the assay environment. 
Metabolic activation of ~ifampicin caused severe 
malformations of the gut, brain, eye, and skeletal system at 
low RA concentrations. Concentrations greater than 1 mgjml 
had a detrimental effect on embryo growth. Embryos exposed 
to the CO-MAS and RA developed normally and growth was not 
inhibited, thus implying the role of P-450 in teratogenesis. 
Malformations induced by RA exposure in Xenopus are similar 
to deformaties found in mammalian models and possibly the 
human. Oral doses of greater than 150 mgjkg in mice and 
rats caused spina bifida in both species and cleft palate 
malformations in the mouse fetus 22 . Similar treatment of 
rabbits had no apparent effect on the developing fetus. 
Greenaway et a1. 23 produced open neural tubes in rats grown 
in vitro and exposed to ~. The response was only observed 
in the presense of an exogenous microsomal monooxygenase 
system. Embryo growth was also reduced but was not 
dependent on the presence of a MAS. In addition, RA has 
been determined to be more problematic during pregnancy than 
several other antituberculosis drugs, such as isoniazid and 
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ethambutol24 • Steen and Stainton-Ellis25 reported 9 
malformations among 202 exposed newborns (4.5%). The 
malformations observed were ane~cephaly {1) ,,. hydrocephalus 
(2), genitourinary 'anomalies (2) ,. dislocated' hip (1), and· 
skeletal reduction deformaties {3).' However, evaluation of 
this information is difficult ,sin~e no information about 
patient selection was included in the report26 • 
Metabolic activation of BP decreased the 96-h ECSO 
(malformation) by 5 to 6 fold. Embryo lethality was not 
affected up to the maximum soluble concentration. Thus, 
bioactivation significantly increased the potential 
teratogenic hazard of BP. Unact·ivated BP induced primarily 
gut, mouth, and skeletal malformations. Bioactivation 
increased the severity of s~eletal deformities, but caused 
, serious brain (microencepha,ly) and eye malformations at low 
BP concentrations. Activation also caused decreased Xenopus 
embryo growth at concentrations greater than 5.0 ugjml. 
Some of the malformati·ons induced by BP in mammalian test 
systems are similar to those observed with Xenopus. Shum et 
ar. 27 found that B-n~phthoflavone-enhanced BP metabolism in 
AKR inbred mice inje~ted (i.p.) with .BP between 50 and 300 
mgjkg was associated·with inc~eased in utero toxicity and 
terata (club foot, -cleft palate and lip, kinky tail, 
' ' 
hemangioma, anophthalmia, and scoliosis). Skeletal kinking 
in Xenopus may bear some relationship to skeletal limb 
defects in mammals13 . Similar terata were also observed in 
B627 and C57BL/628 strain mice after i.p. injectipn, but 
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occurred more frequently than in the AKR strain. Greater 
incidence of anomalies found in the B6 strain has been 
attributed to g,enetic variability in the rate of BP 
biotransformation (i.e. C57BL/6N and B6,strain mice have a 
highly inducible P-450 isozyme (AAH) responsible for BP 
metabolism). 
FETAX can not pharmacologically represent the fetal-
maternal system, however it may provide. an opport~nity to 
compare the developmental toxicity of parent compounds and 
metabolites. such studies have already been ,performed with 
cyclophosphamide and one of its' metabolites 4-
hydroxycyclophosphamide4, and nicotine and a, primary 
metabolite cotinine5 •. 
Metabolic activation did not significantly change the 
developmental toxicity of Zn, ~s indicated by the similarity 
of the TI values., Malformations, in activated and 
unactivated experiments were similar as well. Differences 
in the LCSO values for activated experiments initially 
suggested that some other factor, such as microsomal 
metallothionine, ,might be responsible for the slight 
detoxification of Zn. However, normalization for microsomal 
protein did not si9nificantly change the variability between 
the two experimen~s. If detoxification was the result of 
protein binding, ·normalization should correct this 
variation. Thus, differences were probably due to only 
genetic variability of the embryos used and minor procedural 
variations. Similar results obtained with and without the 
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MAS seem to indicate that the MAS does not appreciably 
affect the caco3 hardness of the test solution. If the MAS 
significantly contributed to the hardness of the test 
solution, a decrease in the developmental toxicity of Zn 
would have been observed. Growth, wh'ich is often the most 
sensitive endpoint measured by FETAX,- was not significantly 
reduced upon activation. Much emphasis placed on MAS 
studies concerns the ability to detect proteratogens. 
However, a successful MAS must not alter the -results of 
direct-acting teratogens. Established direct-acting 
teratogens, such as -~n in Xenopus, should be tested in 
parallel with a metabolic acti,vation system to show that 
results are not affected. Eventually all compounds selected 
for validation of in vitro teratogenesis screening systems 
should be tested with and without the MAS. 
Results from experiments performed with the MAS 
indicate that the developmental toxicity of CD was reduced. 
Bioinactivation of CD decreased the TI at least 2.6 fold 
from approximately 3.9 to 1.5. Embryos exposed to 
metabolic_ally inactivated CD developed markedly better which 
was reflected in the absence of several different types of 
terata observed in unactivated CD,and in embryo growth. 
Whereas 50 ngjml of unactivated CD caused malformations of 
the eye, craniofacial region, and gut, an inactivated 
concentration 5 fold greater induced pericardial edema and 
mouth anomalies. These malformations were not observed in 
any concentration of unactivated CD. A 12 fold increase in 
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inactivated CD was required to elicit brain, craniofacial, 
and skeletal defects. At such high concentrations the 
possibility of malformations caused by unmetaboliz.ed CD may 
be signific·~nt. In general,· 'the severity of malformations 
induced by inactivated CD was significantly less than that 
caused by unactivated CD. Prev~ous studies with CO in other 
animal models are similar to results obtained with FETAX. 
Shepard and Greepaway29 foun~ that c-57 and BALB-C, but not 
Swiss-Webster, strain mice injected on-days 7 through 11 
produced exencephaly, hypognathia, and skeletal reduction 
effects. Exencephaly was found to be the predominant 
malformation in hamsters30 • In the rat, CD was non-
teratogenic in vivo; ho~ever, impaired neural tube closure 
was observed in vitro31 •· Interestingly, the majority of 
Xenopus embryos that'died at concentrations greater than 2.5 
ugjml were arrested during ~eurulation. The addition of a 
MAS to the cultured·whole-rat embryo system caused 
significant inhibition of CD teratogenesis29 • Inhibition of 
teratogenesis was reduced with t~e addition of co. In 
FETAX, ,C<;)-MAS restored much ·of the ,developmentally toxic 
effects of CD including growth inhibition. Based on the 
present evaluation scheme using the TI, inactivated CD has 
' ' 
the potential to be developmentally _hazar~ous. However, 
' ' 
differences in the-types and severity of malformations and 
inhibition of growth reduction upon inactivation, as well as 
reversal of the effects by co, indicate that CD 
teratogenesis may be inhibited by the P-450 system. These 
46 
results suggest the importance of in vitro developmental 
toxicity test systems, including FETAX, in evaluating 
discrepancies between in vivo and in vitro models. 
DMSO seems to be anc effective carrier solvent for FETAX 
at concentrations not exceeding 1%. Several additional 
cosolvents have been tried with FETAX including acetone and 
triethylene-glycol. However, preliminary results indicate 
that acetone i~ not compatible with the MAS. Bioactivated 
acetone proved to be extremely toxic. Further evaluation of 
metabolic activation in teratogenesis with FETAX may 
necessitate the use of other carrier solvents. Formamide, 
ethanol, and glycerol formal have also been studied for use 
as cosolvents, but have not been used in formal validation 
studies (T. H. Dresser, personal communication). We are 
presently investigating the effect of carrier solvent-
toxicant interactions with FETAX. 
Without the ability to metabolize xenobiotics it is 
doubtful that in vitro test systems will be suitable for 
screening human developmental toxicants. Results of tests 
performed with CP4 , nicotine5 , 2-AAF; RA; ,BP, Zn, and CD 
all indicat~ that with an exogenous MAS, FETAX may be able 
to overcome metabolic incompetance and successfully serve as 
a screen in developmental toxicity hazard assessment. Such 
a system should' also provide information on the role of MFO 
metabolism in teratogenesis. By implementing a MAS into the 
FETAX protocol, we may increase the predictive value by 
decreasing the number of false-positive and false-negative 
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test results. 
/ 
48 
ACKNOWLEDGEMENTS 
The authors wish to thank Drs. Margaret Ewing and 
Robert Finch for reviewing the manuscript and Ms. Shirley J. 
Bush, Ms. Charolotte V. Sowell, Mr. James R. Rayburn, and 
Ms. Donna J. DeYoung for their technical assisatance during 
this project. This work was supported by the u.s. Army 
Research and Development Command under Contract No. DAMD17-
88-C-8031, the Oklahoma Center for the Advancement of 
Science and Technology grant No. HR8-3332, a Reproductive 
Hazards in the Workplace Grant No. 15-30 from the March of 
Dimes Birth Defects Foundation, and by a grant from the 
University Center for Water Research at O.S.U. D.J.F. was 
the recipient of a Presidential Fellowship in Water 
Resources from O.S.U. 
The opinions, interpretations, conclusions and 
recommendations are those of the authors and are not 
necessarily endorsed by the U. S. Army. The investigators 
adhered to the "Guide for the Care and Use of Laboratory 
Animals" prepared by the Committee on Care and Use of 
Laboratory Animals of the Institute of Laboratory Animals of 
the Institute of Laboratory Animal Resources, National 
Research Council (NIH Publication No. 86-23, Revised 1985). 
49 
REFERENCES 
1. N. A. Brown, Teratogenicity testing in vitro: Status 
of validation studies. Arch• Toxicol. Suppl. 11, 105-114 
(1987). 
2. G. L. Kimmel, K. Smith, D. M. Kochhar, and R. M. Pratt, 
Overview of in vitro teratogenicity testing: Aspects 
of validation and application to screening. Teratogen. 
Carcinogen._ Mutagen. 2, 221-229 (1982). 
3. J. N. Dumont, T. w. Schultz~'M. Buchanan and G. Kao, 
Frog Embryo Teratogenesis Assay: Xenopus (FETAX)--A 
short-term assay applicable to complex environmental 
mixtures. In Symposium on the Application of Short-term 
Bioassays in the Analysis of Complex'Environmental 
Mixtures III •. ed. by M. D. Waters, s. s. Sandhu, J. 
Lewtas, L. Claxton, N. 'Chernoff, and s. Nesnow. pp. 393-
405. Plenum Press, New York (1983). 
' 4. D. J. Fort, D. A. Dawson and J. A. Bantle, Development 
of a metabolic activation system for the Frog Embryo 
Teratoge~esi~ Assay: _Xenopus (FETAX) • Teratogen. 
Carcinogen~ Mutagen. 8, 251-263 (1988). 
5. D. A. Dawson, D. J. Fort, G. J. Smith, D. L. Newell 
and J. A. Bantle, Evaluation of the developmental 
toxicity of nicotine·and cotinine with Frog Embryo 
' ' 
Teratogenesis Assay: Xenopus (FETAX). Teratogen. 
Carcinogen. Mutagen. 8, 329-338 (1988). 
6. E. J. Freir~ich, Quantitative comparison of toxicity 
50 
of anti-cancer agents in mouse, rat, dog, and monkey. 
Cancer Chemother. Rep. 50, 219-244 (1977). 
7. J.G. Dent, s. Schnell, M. E. Graichen, P. Allen, D. 
Abernathy and D. B. Couch, Stability of activating 
systems for in vitro mutagenesis assays: enzyme 
activity and activating ability following long-term 
storage at -85° c. Environ. Mutagen. 3, 167-179 
( 1981) . 
8. M. M. Bradford, A rapid sensitive method for the 
quantification of microgram quantities of protein 
utilizing the principle of protein-dye binding. Anal. 
Biochem. 72, 248-254 (1976). 
9. T. Nash, The colorimetric estimation of formaldehyde 
by means of the Hantzsch reaction. Biochem. 55, 412-416 
(1955). 
10. G. Lucier, o. McDaniel, P. Brubaker and R. Klein, 
Effects of methylmercury hydroxide on rat liver 
microsomal enzymes. Chem-Biological Interact. 4, 265-
280 ( 1971) • 
11. J. A. Bantle and D. A. Dawson, Uninduced rat liver 
microsomes as a metabolic activation system for FETAX. 
In Aquatic Toxicology and Hazard Assessment, Vol 10. 
ed. by w. J. Adams, G. A. Chapman and w. G. Landis, 
ASTM STP 971, pp. 316-326. American Society for Testing 
and Materials (1987). 
12. c. L. Courchesne and J. A. Bantle, Analysis of the 
activity of DNA, RNA, and protein synthesis inhibitors 
51 
on Xenopus embryo development. Teratogen. 
Carcinogen. Mutagen. 5, 177-193 (1985). 
13. D. A. Dawson and J. A. Bantle, Development of a 
reconstituted water media and preliminary validation of 
the Frog Embryo Teratogenesis Assay - Xenopus 
(FETAX). J. Appl. Toxicol. 7, 237-244 (1987). 
14. D. A. Dawson, E. F. Stebler, s. L. Burks and J. A. 
Bantle, Evaluation of the developmental toxicity of 
metal-contaminated sediments using short-term fathead 
minnow and frog embryo-larval assays. Environ. Toxicol. 
Chern. 7, 27-34 (1988). 
15. u. s. Environmental Protection Agency, Ambient water 
quality for zinc. EPA-440/5-80-079 (1980) . 
16. G. B. Dave, B. Damgaard, M. Grande, J. E. Martelin, B. 
Rosander and T. Viktor, Ring test of an embryo-larval 
toxicity test with zebrafish (Brachydanio rerio) using 
chromium and zinc as toxicants. Environ. Toxicol. Chern. 
6, 61-71 (1987). 
17. P. D. Nieuwkoop and J. Faber, Normal Tables of Xenopus 
laevis (Daudin), 2nd edn. Amsterdam: North Holland (1975). 
18. R. J. Tallarida and R. B. Murray, Manual of 
Pharmacologic Calculations with Computer Programs. 
Springer-Verlag, New York (1980). 
19. D. A. Dawson, D. J. Fort, D. L. Newell and J. A. 
Bantle, Developmental Toxicity Testing with FETAX: 
Evaluation of five compounds. Drug Chern. Toxicol. (in 
press). 
52 
20. T. Izumi, Developmental anomalies in offspring of mice 
induced by administration of 2-acetylaminofluorene 
during pregnancy. Acta. Anat. Nippon. 37, 239-249. 
21. E. Faustman-Watts, J. c. Greenaway~ M. J. Namkung, 
A. G. Fantel and M. R. Juchau,, Teratogenicity in vitro 
of 2-acetylaminofluorene: Role of biptransformation in 
the rat. Teratology 27, 19-28 (1983). 
22. H. Tuchmann-Duplessis and L. Mercier-Parot,.Influence 
d'un antibiotique, la rifampicine, sur le developpement 
prenatal des ronguers. c. R. Acad. Sci. (Paris) 269, 
2147-2149 (1969). 
23. J. c. Greenaway, A. G; Fantel and T. H. Shepard, In 
vitro metabolic activation of rifampicin teragenicity. 
Teratology 23, 37A (1981). 
24. M. R. Holdiness, Teratology of the antituberculosis 
drugs. Early Hum. Dev. 15, 61-74 (1987). 
25. J. s. M. Steen and D. M.' Stainton-Ellis, Rifampicin in 
pregnancy. Lancet 2, 604-605 (1977). 
26. 
27. 
T. H. Shepard, Catalog of Teratogenic Agents, 5th ed. 
pp. 1283-1284, Johns Hopkins Univ.ersity Press, 
Baltimore, MD. (1986). 
s. Shum, N. M. Jensen and D. w. Nebert, The murine Ah 
locus: In utero toxicity.and teratogenesis 
associated with genetic differences in benzo(a)pyrene 
metabolism. Teratology 20, 365-376 (1979). 
28. G. H. Lambert and D. w. Nebert, Genetically mediated 
induction of drug-metabolizing enzymes associated with 
53 
congenital defects in the mouse. Teratology 16, 147-153 
(1977). 
29. T. H. Shepard and J. c. Greenaway, Teratogenicity of 
cytochalasin D in the mouse. Teratology 16, 131-136 
(1977). 
30. M. J. Wiley, Ultrastructural analysis of cytochalasin-
induced neural tube defects in in vivo. Teratology 
19, 53A (1979). 
31. A. G. Fantel, J. c. Greenaway, T. H. Shepard, M. R. 
Juchau and s. B. Selleck, The teratogenicity of 
cytochalasin D and its inhibition by drug metabolism. 
Teratology 23, 223-231 (1981). 
54 
Table ~ Effect of 2-acetylaminofluorene on Xenopus embryo development. 
Treatment Unactivated 
~SOLUTION 
a 
CONTROL-: 
Mortality 
MalformatJ.on 
b a 
MAS- CONTROL-: 
-- -----
Mortality 
Malform tJ.on 
a 
.!! (V/V) ~CONTROL-_:_ 
MortalJ.ty 
MalformatJ.on 
a 
MAS + 1% (V/V) DMSO--:.:_ 
MortalJ.ty 
Ma1formatJ.on 
ac 
~ mg/ml CP-_ 
Trial 1 
5.0 
3.5 
2.5 
5.1 
Mortality 0 
Malformation 20.0 
d ae 
co-MAS-+ 75 ug/ml 2-AAF-..:_ 
Mortality 0 
Malformation 100.0 
f 
LCSO- (ug/ml) 87.0 
(84.0-89.0) 
f 
ECSO- (ug/ml) 6.9 
(6.5-7.3) 
.! 
TI 12.6 
a 
Data presented as percent effect. 
b 
MetabolJ.c actJ.vation system. 
c 
CyclophosphamJ.de. 
d 
Carbon monoxide inactJ.vated MAS. 
e 
Trial 2 
0 
2.5 
0 
5.0 
0 
10.0 
0 
85.0 
90.0 
(88.0-93.0) 
7.4 
(7.0-8.0) 
12.2 
Activated 
Trial 1 Trial 2 
1.3 0 
2.5 5.0 
5.0 0 
3.4 5.0 
0 0 
5.0 5.0 
7.5 0 
15.0 12.5 
100.0 100.0 
0 0 
100.0 100.0 
45.0 40.0 
(26.0-78.0) (32.0-58.0) 
2.6 2.5 
(0.4-9.0) (2.0-3.0) 
17.3 16.0 
UnactJ.vated column represents data for embryos exposed to 75 ug/ml 2-AAF alone. 
f 
Determined by LJ.tchfJ.eld-WJ.lcoxon probit analysis wJ.th 95% percent confJ.dence 
J.nterval J.n parenthesis. 
g 
96 h LC50/96 h EC50 (malformatJ.on). 
Table II. Effect of rifampicin on Xenopus embryo development. 
Treatment UnactivatEld 
FETAX SOLUTION 
a 
CONTROL-: 
Mortahty 
Malforma t:ton 
b a 
MAS CONTROL-: 
-----
Mortality 
Malformation 
a 
_!! (V/V) DMSO CONTROL-_ 
Mortality 
MalformatJ.on 
a 
MAS + _!! (V /V) DMSO-_:_ 
Mortality 
Malformat1on 
ac 
.i:..Q_ ~ CP-_ 
Trial 1 
1.9 
3.4 
0 
5.0 
MortalJ.ty 0 
Malformation 5.0 
d ae 
co-MAS-+~ mg/ml RA-_ 
Mortality 0 
Malformation 5.0 
f g 
LC50- (mg/ml) )2 .0 
f 
EC50- {mg/ml) )2.0 
h 
TC 
a 
Data presented as percent effect. 
b 
MetabolJ.c act1vat1on system. 
c 
CyclophosphamJ.de. 
d 
Carbon monoxJ.de inactivated MAS. 
e 
Trial 2 
1.9 
5.1 
0 
2.5 
0 
5.0 
13.3 
15.4 
)2.0 
)2.0 
Activated 
Trial 1 Trial 2 
2.5 0 
5.1 0 
2.5 0 
5.1 5.0 
0 0 
5.0 0 
2.5 0 
10.3 5.0 
100.0 100.0 
0 0 
15.4 10.0 
1.40 1.35 
(1.24-1.56) (1.26-1.46) 
0.53 0.47 
(0.45-0.63) (0.39-0.55) 
2.6 2.9 
unact:tvated column represents data for embryos exposed to 2.0 mg/ml RA alone. 
f 
DetermJ.ned by Litchfield-Wilcoxon probit analys1s with 95 percent confidence 
J.nterval in parenthesJ.s. 
g 
Lim1t of solubJ.lJ.ty in 1% (v/v) DMSO. 
h 
96 h LCS0/96 h EC50 (malformatJ.on). 
Table~ Effect of benzo(a)pyrene on Xenopus embryo development. 
Treatment Unactivated 
FETAX SOLUTION 
a 
CONTROL-: 
----
Mortality 
Malformat~on 
b .!!. 
MAS- CONTROL 
Mortality 
Malformat~on 
a 
_!! (V/V) DMSO CONTROC_ 
Mortahty 
Malformat~on 
a 
MAS + 1% (V/V) DMSO-..:_ 
Mortahty 
Malformat1on 
ac 
i!Q_~ CP-_ 
Trial 1 
0 
0 
2.5 
5.0 
Mortal1ty 0 
Malformat1on 15.0 
d ae 
CD-MAS-+ 10 ug/ml BP-_ 
Mortal1ty 0 
Malformation 
f g 
LC50- (ug/ml) >10.0 
f 
EC50- (ug/ml) 12.0 
(6.0-20.0) 
h 
>0.8 
a 
Data presented as percent effect. 
b 
Metabolic act1vation system. 
c 
Cyclophospham1de. 
d 
Carbon monox1de inact1vated MAS. 
Trial 2 
0 
3.4 
0 
0 
0 
15.0 
0 
>10.0 
10.0 
(8.0-12.0) 
>LO 
Activated 
Trial 1 Trial 2 
0 0 
0 3.4 
0 3.4 
2.5 3.4 
2.5 0 
3.4 0 
0 0 
15.0 3.4 
100.0 100.0 
0 0 
40.0 33.3 
>10.0 >10 .o 
1.5 1.8 
( 1.0-2 .4) (1.2-3.0) 
>6.7 >5.6 
e 
Unactivated column represents data for embryos exposed to 10 ug/ml BP alone. 
f 
Determ1ned by Litchfield-Wilcoxon probit analysis with 95 percent confidence 
interval in parenthesis. 
g 
Lim1t of solub1lity 1n 1% (v/v) DMSO. 
h 
96 h LCS0/96 h ECSO (malformation). 
Table rJ • Effect of ZnSO on Xenopus embryo development. 
4 
Treatment Unactivated Activated 
FETAX SOLUTION 
a 
CONTROL-: 
Mortahty 
Malformation 
b a 
MAS- CONTROL-: 
Mortality 
Malformat~on 
ac 
~ mg/ml CP-_ 
Mortahty 
Trial 1 
0 
5.0 
0 
Ma1format~on 0 
d e af 
CD-MAS- + 85 ug/ml- ZnSO 
--4-
Mortahty 0 
Malformat~on 100.0 
35.0 
(33.9-36.1) 
LC50 ~ Zn/ug protein) 
~ 
EC50 (ug/ml) 2.22 
(1.79-2.76) 
h 
TI- 15.8 
a 
Data presented as percent effect. 
b 
Metabolic activat1on system. 
c 
Cyclophospham1de. 
d 
Carbon monoxide inactivated MAS. 
e 
Trial 2 Trial 1 
0 0 
2.5 1.3 
2.5 
0 
0 100.0 
0 
0 0 
100.0 100.0 
33.8 40.0 
(33.2-33.4) (39.7-40.3) 
1.72 
(1. 72-1. 75) 
3.15 2.92 
(2.80-3.54) (2.55-3.35) 
10.7 13.7 
Concentrat1on not normalized to 100 ug/ml hardness (as CaCO ). 
3 
f 
Trial 2 
0 
2.5 
3.4 
3.6 
90.0 
100.0 
0 
100.0 
33.4 
(32.7-34.1) 
1.39 
(1.36-1.42) 
2.85 
(2.64-3.09) 
11.7 
Unactivated column represents data for embryos exposed to 85 ug/ml Zn alone. 
g 
Determined by L1tchfield-W1lcoxon prob1t analys1s w1th 95 percent conf1dence 
interval 1n parenthesis. Concentrations normal1zed to 100 ug/ml hardness 
14,15 
(as CaCO ) 
3 
h 
96 h LCS0/96 h EC50 (malformatlon). 
Table V. Effect of Cytochalasin D on Xenopus embryo development. 
Treatment Unactivated 
FETAX SOLUTION 
a 
CONTROL-: 
Mortality 
Malformat1.on 
b a 
MAS- CONTROL-: 
----
Mortality 
Malformation 
a 
1% (V/V) DMSO-..:_ 
Mortall.ty 
Malformation 
a 
MAS + 1% (V/V) DMSO-..:_ 
Mortall.ty 
Malformation 
ac 
i:..Q_ mg/ml CP-_ 
Trial 1 
3.8 
2.5 
Mortal1.ty 0 
Malformation 0 
d ae 
co-MAS- + .!.:Q ug/ml CD-_ 
Mortality 7 5 • 0 
Malformation 100 .o 
f 
LC50- (ng/ml): 490 
(376-638) 
f 
EC50- (ng/ml): 121 
(86-170) 
4.1 
a 
Data presented as percent effect. 
b 
Metabolic activat1.on system. 
c 
Cyclophospham1.de 
d 
Trial 2 
2.5 
3.8 
6.7 
3.6 
3.4 
3.4 
80.0 
100.0 
433 
(313-599) 
121 
(77-199) 
3.6 
Carbon monox1.de 1.nactivated metabolic act1.vation system. 
e 
Activated 
Trial 1 Trial 2 
1.3 1.3 
3.8 5.1 
2.5 2.5 
2.6 5.2 
0 0 
5.0 5.0 
0 0 
7.5 10.0 
100.0 100.0 
96.7 95.0 
100.0 100.0 
883 728 
(765-1020) (637-831) 
541 551 
(458-638) (486-625) 
1.6 1.3 
Unactl.vated column represents data for embryos exposed to 1 ug/ml CD alone. 
f 
Determined by L1.tchf1.eld-Wilcoxon prob1.t analys1.s Wl.th 95 percent conf1.dence 
interval 1.n parenthesis. 
g 
96 h LC50/96 h EC50 (malformatl.on). 
FIGURE LEGENDS 
FIGURE 1 - Representative growth curves, presented as 
percent of FETAX solution control, for Xenopus embryos 
exposed to unactivated <•> and bioactivated (~) 2-AAF 
for 96 h. (e) represents the additive growth inhibiting 
effects of the MAS + DMSO and unactivated 2-AAF 
treatments.· 
FIGURE 2 - Representative growth curves, presented as 
percent of FETAX solution control, for Xenopus embryos 
exposed to unactivated <•> and bioactivated (~) RA. 
(e) represents the additive growth inhibiting effects of 
the MAS ~ DMSO and unactivated RA treatments. 
FIGURE 3 - Representative growth curves, presented as 
percent of FETAX solution control, for Xenopus embryos 
exposed to unactivated <•) and bioactivated ( ~) BP for 
96 h. (e) represents the additive growth inhibiting 
effects of the MAS + DMSO and unactivated BP treatments. 
FIGURE 4 - Representative growth curves, presented as 
percent of FETAX solution 'control, for Xenopus embryos 
exposed to unactivated <•> and Zn plus the MAS (~) for 
96 h. (e) represents the additive growth inhibiting 
effects of the MAS and unactivated Zn treatments. 
Figure 5 - Representative growth curves, presented as 
percent of FETAX solution control, for Xenopus embryos 
exposed to unmetabolized <•> and bioinactivated CD (~) 
for 96 h. (e) represents the additive growth inhibiting 
effects of the MAS + DMSO and unmetabolized CD treatments. 
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USING EXOGENOUS METABOLIC ACTIVATION SYSTEMS 
WITH FROG EMBRYO TERATOGENESIS ASSAY -
XENOPUS (FETAX) 
Douglas J. Fort and John A. Bantle* 
_Department of Zoology 
430 Life Sciences West 
Oklahoma State University 
Stillwater, OK 74078 
Running Head: Teratogenic activity of isoniazid in vitro 
*Author to whom correspondence should be addressed 
66 
ABSTRACT 
The developmental toxicity of isoniazid (INH) and 
metabolites acetylhydrazide (AH) and isonicotinic acid (INA) 
were examined with Frog Embryo Teratogenesis Assay - Xenopus 
(FETAX). Late Xenopus laevis blastulae were exposed to INH, 
AH, and INA for 96-h in two separate static-renewal tests 
with and without the presence of three differently induced 
metabolic activation systems (MAS) . The MAS consisted of 
uninduced, Aroclor 1254-induced, and INH-iriduced rat liver 
microsomes. Addition of the INH-induced MAS decreased the 
96-h LC50 of INH and AH approximately 1.6-fold and 6.9-fold, 
respectively. The 96-h EC50 (malformation) of INH increased 
slightly (ca. 1.5-fold), decreasing the Teratogenic Index 
[TI=96-h LC50/96-h EC50 (malformation)] nearly 2.3-fold. 
The 96-h EC50 (malformation) of,AH increased approximately 
2.3-fold, decreasing the ,TI value 17.5-fold. INA yielded a 
TI value of approximately 2.6. Neither the uninduced MAS 
nor the Aroclor 1254-induced MAS had an effect on any of the 
compounds tested and none of the MAS affected the 
de~elopmental toxicity of INA. cBased on TI values, embryo 
growth, and types and severity of induced malformations, 
INH, AH, and INA all scored as potential developmental 
toxicants. Results from this study suggest that mixed 
functional oxidase metabolism may alter the developmental 
toxicity of INH in vitro by producing a more embryolethal, 
but less teratogenic species than INH or AH themselves. 
Results are indicative of the utility and versatility ,of 
67 
FETAX in the rapid screening of developmental toxicants. 
Key Words: bioactivation, developmental toxicity, 
teratogenesis, cytochrome P-450, Xenopus 
68 
INTRODUCTION 
Several alternative developmental toxicity screening 
systems to traditional tests employing pregnant mammals have 
been developed and utilized to minimize burdens associated 
with time,, cost., and concern for animal welfare (1). One 
such alternative_system is the Frog Embryo Teratogenesis 
Assay- Xenopus (FETAX) (2) .. FETAX is 'a 96-:-h,- whole-embryo, 
static-renewal bioassay designed to screen for potential 
developmental toxicants in the environment and the 
workplace. To increase the predictability of FETAX an 
exogenous metabolic activation system (MAS) consisting of 
Aroclor 1254-induced rat liver mtcrosomes was developed (3) 
and evaluated (4). The developmental toxicity of nicotine 
and primary metabolite cotinine (5); as well as, 
diphenylhydantoin and hydroxylated phenytoin metabolites (6) 
have also been assessed with this system. 
Isoniazid (INH) is one of the most widely used 
tuberculostatic drugs available today. Altho~gh only a few 
studies with mammalian systems (7) and occasional cases in 
humans (8-10) have suggested INH to have tera~ogenip 
activity in vivo, INH was recently shown to.have a high 
teratogenic potential in FETAX .(11) and the Hydra assay (12) 
when tested without an in vitro MAS. 
The primal:y metabolic pathway for the metabolism of INH 
is via acetylation to acetylisoniazid and subsequent 
hydrolysis to acetylhydrazide (AH) and isonicotinic acid 
(INA) (13). AH is further oxidized by cytochrome P-450j to 
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N-hydroxyl- acetylhydrazide, an unstable derivative fragment 
capable of forming an acetyl radical (carbonium ion) (14). 
In the present investigation, we attempt to determine 
if the positive results obtained by the in vitro assay 
systems are related to the lack of maternal metabolism. 
Specifically, the developmental toxicity of INH and 
metabolites AH and INA is evaluated with and without the 
addition of various exogenous bioactivation systems. 
Results of this study support the continued use of FETAX and 
an exogenous MAS in the rapid screening of potential 
developmental toxicants, as well as its utility in 
investigating possible toxicological mechanisms of 
teratogenesis. 
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MATERIALS AND METHODS 
Microsome Isolation 
Rat liver microsomes were prepared as described· 
previously (3). Adult male Sprague-Dawley rats (100-150 g) 
were treated with either Aroclor 1254 (Monsanto, st. Louis, 
MO) or INH (Sigma, st. Louis, MO) . Aroclor 1254 (500 mgjKg) 
in corn oil was injected intraperitoneally 5 d prior to 
microsome preparation (15). INH (0.1% wjv, pH 7.4) was 
administered via drinking wa~er for 10 consecutive days 
prior to microsome isolation (13). All rats were fasted 24 
h prior to microsome preparation. 
Protein content was determined by the method of 
Bradford (16) (Bi9Rad, Richmond, CA). Cytochrome P-450 
activity was inferred by measurement of formaldehyde 
generated from the N-demethylation of aminopyrine (17) and 
N -ni trosodimethylamine ( 1~U under standard assay conditions 
described previously (19).- Units are expressed as uM 
formaldehyde generated/min. S~veral aliquots of microsomes 
were chemically reduced with dithionite and pretreated with 
carbon monoxide (CO-MAS) to selectively inactivate P-4'50 
activity (20). 
Animal Care and Breeding 
\ Xenopus adult care, breeding, and embryo collection were 
\ 
performed as described'by Dawson and Bantle (21). 
Assay Protocol 
For experiments without the MAS, groups of 20 embryos 
were placed in 60-mm covered plastic Petri dishes 
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(Fisher Scientic, Houston, TX) with varying concentrations 
of the appropriate test compound. INH, AH (Aldrich, 
Milwaukee, WI), INA, cyclophosphamide (CP) (both from Sigma, 
st. Louis, MO) were dissolved in appropriate volumes of 
FETAX solution, a reconstituted water medium suitable for 
the culture of,Xenopus embryos (21). For each compound 10-
16 concentrations were tested with replicates. Four 
separate dishes o+ 20 embryos were exposed to FETAX solution 
alone and designated FETAX solution controls. Each 
treatment dish contained a total of 8 ml· of solution. 
Since the purchased INH was nqt-anhy.drous, stock 
concentrations were measured spectrophotometrically at 266 
nm. 
Tests includi~g the MAS were also conducted in 
duplicate with 20 embryos per replicate concentration. Each 
activated treatment received 60 ugjml of either uninduced, 
Aroclor 1254-, or I~H-induced microsomal protein, an NADPH 
generating system, and a penicillin-~treptomycin mixture to 
control bacterial growth (3-6). For each compound 8-12 
concentrations ~ere tested. Controls including FETA~ 
solution, each MAS, co-gassed-MAS+ toxicant (negative 
control), CP (FETAX ref~rence proteratogen (4-6)] and AH 
(positive controls), and unactivated toxicant were run 
simultaneously with each experiment. 
For each compound, one range-finder and two definitive 
dose-response experiments were conducted with and without 
the MAS. The pH of all stock solutions was 7.0. Embryos 
72 
were cultured at 23±1°C throughout each test. All solutions 
were changed every 24 h of the 4-d test and fresh solutions 
were added. Dead embryos were removed at this time. 
Following 96-h of exposure, surviving embryos were fixed in 
0.7% formalin (pH 7.0). The number of live malformed larvae 
and the stage of development (22) were ascertained using a 
dissecting microscope. 
Data Analysis 
Litchfield-Wilcoxon probit analysis (23) was used to 
determine the 96-h median lethal concentration (LCSO) and 
the concentration inducing gross terata in 50% of the 
surviving embryos (ECSO) . The 95% confidence limits were 
calculated as well. A measure of the teratogenic potential, 
the Teratogenic Index (TI) was calculated by taking the 
ratio of the 96-h LCSO to the 96-h ECSO (malformation) (3-
6,11). Head-tail length of surviving embryos was measured 
as an index of growth using an IBM-AT compatible computer 
and Sigma Scan (Jandel Scientific, Corte Madera, CA). 
digitizing software. Minimum concentrations to inhibit 
growth (MCIG) (11,20) were determined for each experiment 
with the t-Test (p<O.OS). 
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RESULTS 
Microsomal N-Demethylase Activity 
Preliminary results determined that Aroclor 1254-induced 
microsomal' aminopyrine-N-demethylase' activity ( 6. 3 8±0. 11 
U/mg protein) was significantly greater,than either the 
uninduced or the INH-induced microsomal 'protein (3.50±0.11 
and 3.41±0.2~ U/mg protein, respectively). However, INH-
induced microsomal N-nitrosodimethylamine-N-demethylase 
activity (3.67±0.95 Ujmg protein) was significantly elevated 
compared to either the uninduced or the Aroclor 1254-induced 
protein (1.34±0.39 and 0.55±0.92 Ujmg·protein, respectively) 
[N=6 for all treatments; P=0.05 for both]. 
FETAX Control Results 
In all tests conducted, FETAX solution control embryo 
mortality and malformation rates were <2.5%. Mortality and 
malformation rates for each MAS control were <4.0%. Control 
embryos exposed to 4.0 mgjml unactivated CP exhibited 
mortality and malformation rates <8%. Mortality and 
malformation rates for 3. 0 mg/ml AH wer,e <2% and 100%, 
respectively. Embryos subjected to 4-. d mgjml CP and either 
' - ' 
the uninduced MAS or the INH-induced MAS exhibited mortality 
and deformity rates <25%, whereas no,less than 95% of those 
'' 
exposed to 4.0 mgjml CP and the Aroclor 1254-induced MAS 
died. Survivors of the latter treatment were severely 
malformed. Exposure of control embryos to 3.0 mgjml AH and 
the INH-induced MAS produced mortality and malformation 
rates of >87.5% and 100%, respectively. 
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Isoniazid 
Results from te~ts with INH are presented in Table VI. 
The mean unactivated 96-h LC50 and EC50 (malformation) of 
both definitive trials were 9.99 mgjml and 0.28 mgjml, 
respectively, producing an average TI value of 35.7. 
Bioactivation with the uninduced-MAS and Aroclor 1254-MAS 
produced a mean.96-h LC50 of 8.76 mgjml and 8.90. mgjml, 
respectively. Inclusion of the INH-MAS reduced the mean 96-
h LC50 approximately 1.6-fold to 6.34 mgjml, however, the 
96-h EC50 (malformation) was increased to a mean value of 
0.42 mgjml. The TI value was reduced nearly 2.3-fold to a 
mean value of 15.3 by the addition of the INH-MAS. Average 
MCIG values for INH were 2.3, 2.5, and 3.0% of the 96-h LC50 
for unactivated, uninduced-MAS, and ·Aroclor 1254-MAS 
activated treatments, respectively, and 2~0% of the 96-h 
LC50 for those exposed to the INH-MAS. Concentration ranges 
and teratological effe9ts of the.various INH treatments are 
presented in Table IX. 
Acetylhydrazide 
Tne results of experiments'performed with AH. are shown 
in Table VII. The mean 96-h LC50 of both unactivated AH 
trials was 12.42 mgjml. The average 96-h EC50 
(malformation) was 0.05 mgjml, yielding a mean TI value of 
202.0. Addition of the uninduced-MAS and Aroclor 1254-MAS 
produced a mean 96-h LC50 value of 10.63 mgjml and 11.14 
mgjml, respectively. The 96-h mean EC50 (malformation) was 
0.06 mgjml with the addition of either the uninduced system 
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or the Aroclor 1254-MAS. The TI values for the uninduced-
MAS and Aroclor 1254-MAS treatments ranged from 170.5 to 
220.6 and 162.0 to,218.6, respectively., Inclusion of the 
INH-MAS decreased the 96-h LC50 approximately 7-fold to an 
average of 1.8 mgjml, but increased the,96-h EC50 
(malformation) 2.7.-fold to mean·o~ 0.12 mgjml. The TI was 
reduced nearly 18-fold- to 16.0. MCIG values varied only 
slightly in the unactivated ,and metabolical~y- activated 
treatments ranging from 0.3% to,1.0% of the 96-h LC50. 
Teratological concentration ranges and ~iological effects 
are shown in Table IX. 
Isonicotinic Acid 
Results from tests conducted with INA are presented in 
Table VIII. Mean unacti~at~d, uninduced-MAS, Aroclor 1254-
MAS, and INH-MAS activated'96-h LC50 values of INA were 
3.13, 3.28, 3.29, and 3.29 mgjml, respectively. The average 
unactivated 96-h EC50 (malformation) was 1.26 mgjml yielding 
a mean TI value of 2.6. The mean 96-h EC50 (malformation) 
for the uninduced-, Aroclor 1254-, and INH-MAS activated 
treatments were 1.'5~, 1.52, and'1.53 mgjml. Respective mean 
TI values for the uninduced-MAS, Aroclor 1254-MAS, and INH-
MAS bioactivated treatments were _2.~,· 2.2, and 2.2. MCIG 
values ranged from a low of 30.4% recorded with the Aroclor 
1254 activated treatment to 39.6% (% of the 96-h LC50 for 
both) observed in embryos exposed to INA alone. Table IX 
lists the types of malformations and terata-inducing 
concentration ranges of the INA treatments. 
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DISCUSSION 
Results from this study suggest that MFO metabolism may 
have an impact on the developmental toxicity of INH in vitro 
by producing a more embryolethal, but less teratogenic 
species than INH or acetylated metabolite, AH, themselves. 
Data obtained from the preliminary enzyme assays, as well 
I 
as, the two positive FETAX controls CP for the Aroclor 1254-
induced and AH for the INH-induced system, were indicative 
of an active P-450 metabolic system. Furthermore, the 
similarity of results between unactivated INH or unactivated 
AH treatments and the same treatments accompanied by co-
inactivated MAS, including rates of mortality and 
malformation, types and severity of deformities, and embryo 
growth, further suggests that P-450 may affect the 
developmental toxicity of INH. 
Typically, the teratogenic potential of chemicals 
evaluated with FETAX is based on TI values, embryo growth, 
and the types and severity of induced terata. Generally, TI 
values <1.5 signify low teratogenic potential because there 
is little separation between concentrations which induce 
malformations, but do not cause embryolethal effects and 
concentrations which are lethal. Greater TI values indicate 
an increased potential for teratogenesis since a greater 
chance exists for embryos to be malformed in the absence of 
significant embryolethality (11). Since an adult to 
developmental (A/D) toxicity ratio (24) is not practicable 
with FETAX, the types and severity of malformations are 
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considered so that compounds with TI values <1.5 that 
produce severe deformities in major organ systems may still 
be considered to pose a developmental hazard, usually as 
embryo to~ins (21). 
The MCIG expressed as a percent of the toxicant LC50 
has also proven useful in evaluatin~ developmental toxicity 
(5,7,11). Dawson et.al. (11) suggest that the MCIG of 
compounds posing a high developmental hazard will be <30% of 
the 96-h LC50. 
Based on this evaluation scheme, unmetabolized INH and 
AH possess significant teratogenic potential, wh~reas 
unmetabolized INA h~s a lesser,potential to induce terata. 
Results obtained with,unactiv.ated INH are similar to those 
obtained by Dawson et al. (11). Addition of the INH-MAS 
decreased the 96-h LC50, however, it also increased the 
concentration required to elicit malformations. INH (11) 
and AH (25) have been previously· shown to cause 
osteolathyrogenic malformations in Xenopus which is 
consistent with the defects observed in this study. 
Osteolathyrogens disrupt the polymerization of connective 
tissue which are important in the development of the axial 
skeleton (25). Metabolism of IN~ and AH reduced the 
incidence of osteolathyrogenic malformations and increased 
' ' 
the concentration of both compounds required to induce 
skeletal kinking (see Table IX). Greater concentrations of 
test material were, therefore, required to induce skeletal 
malformations in the presence of the INH-MAS. Defects of 
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this type at higher concentrations may have been due to a 
greater proportion of the unmetabolized drug compared to the 
lower concentration tr~atments. In addition, no skeletal 
defects were associated with INA treatment, either-with or 
without metabolic supplementation. The reduction of 
skeletal defects appears to be the. result of metabolic 
alteration of the hydrazino moiety [-H2N-N(H)-C(=O)-] of INH 
and AH. Schultz et al. ( 2 6 ). determined that thi~ molecular 
substructure is correlated with the inductiqn of 
osteolathyrism and alteration of the hydraz.ino group sharply 
reduces skeletal defects, whereas alteration of the carbonyl 
moeity elicits a graded reduction in effect. Similar rates 
of skeletal defects in co-inactivated MAS and INH, AH and 
identical unacti vated trea,tments further suggest the role of 
MFO metabolism in the reduc.tion of the teratogenic potential 
of INH. 
Typically, the MCIG is a sensitive endpoint in FETAX. 
Both INH and AH inhibited embryo growth at concentrations 
<4% and <1% of the compound LC50, respectively. INA did not 
have as much of an impact on embryo· growth reduction 
(approximately <40% of LC50). Inclusion of the various MAS 
had no significant eff~c;t on thegrowth inhibition 
associated with any of the compounds. 
' ' 
With the widespread use of isoniazid as an 
antituberculosis drug, it is surprising that evaluation of 
the developmental toxicity has not been more rigorously 
pursued with mammalian models. Of the few reported cases of 
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INH-induced terata in mammals including the human, the 
malformations recorded were similar to those observed in 
FETAX. Dluzniewski and Gasol-Lewinska (7) found INH to have 
teratogenic activity in the- rat, but not in the rabbit. 
Wistar rats injected with 0.31 to 3.1 mg/Kg INH on d 6 to 14 
yielded fetuses with abnormally developed cranial bones. 
Rabbits treated with 1.5 to 5.0 mg/Kg INH produced no 
malformed fetuses. In addition, no anomalies were detected 
in Swiss mice subjected to approximately 50 mgjKg INH during 
d 1 to 4 and 10 to 13 of pregnancy (27). Conflicting 
results have been reported in humans as well. An 
examination of 74 exposed infants (28) and 19 children (29) 
found no increase in congenital defects. However, Heinonen 
(8) observed 10 malformed children from 85 mothers (11.8%) 
exposed to INH during the first four months of pregnancy. 
Severe encephalopathies were reported in five children from 
mothers exposed to INH (9). Warkany (10) has extensively 
reviewed the effects of tuberculostatic drugs in human 
pregnancy suggesting a small association of defects with 
INH. Variable metabolizing capacities may in part explain 
the diverse array of results obtained with mammalian 
species. 
Differences in the developmental toxicity of 
metabolized INH and AH probably reflect differing 
complexities in the routes of metabolism. INH requires 
acetylation prior to microsomal oxidation, whereas AH may be 
directly oxidized by P-450j. Thus, metabolic conversion of 
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INH to N-hydroxylacetylhydrazide is less efficient in vitro 
than is the conversion of AH to the same metabolic 
endproduct. 
Neither the uninduced or the Aroclor 1254-induced MAS 
had any significant effect on any of the compounds tested in 
this study. The lack of effect with these two systems is 
consistent with the finding that Aroclor 1254 significantly 
decreased N-nitrosodimethylamine-N-demethylase activity [a 
measure of P-450j activity] compared to the uninduced and 
INH-induced systems. Repression of P-450j activity by 
Aroclor 1254 has been shown previously, as well (30). 
Several drugs and compounds besides INH and AH have been 
shown to be metabolized by P-450j including pyrazole, 
imidazole, acetone, trichloroethylene, N-nitroso-
dimethylamine, and ethanol (18). Thus, Aroclor 1254-induced 
liver microsomes may prove to be inefficacious as exogenous 
metabolic activation systems for in vitro developmental 
toxicity screening systems in these situations. To increase 
the predictability of the MAS routinely used by FETAX, we 
are currently testing mixtures of microsomes induced by a 
broad-spectrum of P-450 inducing agents. 
Without the ability to metabolize xenobiotics, it is 
doubtful that in vitro tests, including FETAX, would be 
suitable for screening human developmental toxicants. 
Results from previous studies with FETAX and an exogenous 
MAS (3-6) suggest that FETAX may be able to overcome the 
obstacle of maternal metabolism. Since FETAX is an in vitro 
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system providing abiotic exposure of toxicants including 
metabolites, the pharmacological relationship between the 
fetal and maternal systems has been oversimplified. 
However, FETAX provides an opportunity to compare the 
developmental toxicity of parent compounds to metabolites 
and possibly generate information concerning toxicological 
mechanisms of action (6). 
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CONCLUSIONS 
Tests of INH, AH, and INA with FETAX indicated that 
each has the potential to be te~atogenic. However, 
reduction in TI values and induced malformations for both 
INH and AH'upon metabolism compared to these compounds alone 
may indicate this compound and its metabolite could be more 
embryotoxic than teratogenic in,ma~alian systems. 
Metabolic conversion of INH and AH to reactive metabolites 
increased the concentration required to induce terata. INA 
possessed a much lower teratogenic potential than INH or AH, 
as well. These results further suggest that positive 
' ' 
results obtained in several in·vitro developmental toxicity 
assays may be the result of metabolic incompetence 
emphasizing the importance of exogenous MAS for in vitro 
teratogenesis assays. This study is indicative of the 
utility and the versatility of FETAX in screening 
developmental toxicants. 
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a 
Table VL llnalysi• of the Devel-ntal Tozic:ity of Iaoniazid (Illll) wl th FE'DIX. 
'I'RI'!ImW2f1' 'llDD 
' IW.faltii!D u:so liCSO TI ICIG (N) (N) I .Vall (llg/111) 11119/al) 
r• of LC50( 
:!!:!! .!!h 
2 
FE'DIX Solution 0 1.6 
(320) 1320) 
uninduc:ed-fii\S 0 2.5 
(80) (80) 
Aroc:lor 1254-fiiiS 1.3 2.6 
(80) (79) 
lliiHII\S 0 3.8 
(80) (80) 
4. 0 a;/111 CP 0 0 
(80) (80) 
3.0 llg/al All 0 100.0 
(80) (80) 
llnin<IIIC'ed-fiiiS + 4.0 a;/al CP 2.5 20.5 
(80) (78) 
Aroc:lor 1254-fiiiS + 4.0 IIIJ/•1 CP 100.0 
'(80) 
lliiHII\S ,+ 3.0 a;/111, All 92.5 100.0 
(80) (6) 
CXHJrun<luc:ed-fiiiS + 9.5 IIIJ/111 Illll 47.5 100.0 
(80) (42) 
CD-Aroc:1or 1254-111\S + 9 • 5 llg/111 lNII 56.3 100.0 
(80) (35) 
CD-IIIIHIAS + 6.5 oo9/al Illll 12.5 100.0 
(80) (70) 
IIIII 9.86 10.11 0.27 0.29 36.5 34.9 0.2 
(9.55-10.19) (9. 76-10.47) (0.24-0.30) (0.26-Q.32) (2.0( 
!Jnirduce<HIIIS + INII 8.90 8.61 0.30 0.2P 2q 7 10.8 0.2 
(8.67-9.14) (8.3D-8.93) (0.27-0.32) (0. 25-0. 30) (2.21 
Aroc:1or 1254-fiiiS + INH 9.15 8.65 0.29 0.30 31.6 2n.e 0.25 
(8.91-9.39) (8. 40-8. 91) 10.27-0. 32) (0.28-0.33) (2. 7( 
INlHV\S + Illll 6.14 6.54 0.39 0.44 15.7 14.9 0.1 
(5.82-6.48) (6.21-6.89) (0.35-0.44) (0.4D-0.48) (1.6( 
a 
Represents the results of 'two definitive dose-r- ezperi..,nts with and without ~ach of the ..,tabolic act1vation 
syst"""' (unirduc:ed, Aroc:lor 154-inluc:ed, an! isoniazicl-inluced (Illll). FE'Jl'.X solution, ..,tabolic ac:tivatlon systea~ (liAS), 
cyclopbo..p..ide (CP) (poeitin c:ontrol (4-6) I,' acetylhydrazlde (All) IP>Sitive centro!), an! carbon monox1de 1nact1vated liAS 
(co-HAS) + toxicant (fte9atlve c:ontrol( c:ontrols were perfor..:t conc:urrently with each experi..,nt. Median lethal (l.C50J am 
teratogenic (lit:50) c:oncentrat1ona were detersined by Litc:hfielcl-tlilcoxon problt analysis (23) w1th 95' c:onfldence 1ntervals 1n 
p.u.,.,tbeaes. Teratogenic Inlices (Tl) were calculated by taking the rat1o of the 96-h LCSO to the 9&-h Et:SO (malformattonl. 
HlnliiUII concentrations to Inhibit 9rowth (ICIGI were detemined by the T-test (p<0.051. 
2 
0.25 
(2.~) 
0.23 
(2. 7) 
0.28 
(3.2( 
0.15 
(2.3( 
TableVll. Analysis of the Develq:.-ntal Toxlcity of Acetylhydrazide (All) v1th rem.x. a 
'!1lEI\'l'llfJI'l' t DEAD 'IWitRim LC50 a::so TI PCIG (H) (H) (lllg/111) 11119/1111) long/Ill) 
(t of LCSO) 
~!!!:. 
1 2 2 
f1':llUI Solution 0.3 2.2 
(320) (319) 
uninducecl-fW! 0 2.5 
(80) (80) 
1\roc:lor 1254-fW! 1.3 2.6 
(80) (79) 
-
1.3 1.3 
(80) (80) 
4.0 ong/1111 CP 1.3 3.8 
(80) (79) 
3.0 ong/1111 All 0 100.0 
(80) (80) 
Urlinducecl-fW! + 4.0 ong/lll CP 11.3 23.6 
(801 (71) 
Aroc:lor 1254-fWI + 4.0 ong/llll CP 95.0 100.0 
(80) 141 
INIHWl + 3.0 ong/1111 All 90.0 100.0-
(80) (8) 
CXHJi.induced-IIIIS + 12.0 ong/llll AH 61.3 100.0 
(80) (31) 
CX>-1\roc:lor 1254-fll\5 + ~2.0 ong/•1 AH 60.0 100.0 
(80) (32) 
a:>-INIHWl + 2.5 1119/lll AH 3.8 100.0 
(80) (77) 
AH 12.39 12.44 0.05 0.04 247.8 311.0 0.04 0.05 
(11.98-12.81) (12.11-12. 77) (0.04-Q.07) (0.03-o.07) (0.3) (0.4) 
Url!nduced-IIIIS + All - 11.03 10.23 0.05 0.06 220.6 170.5 0.05 0.07 
(10.68-11.391 (9. 98-10.48) (0.04-o.06) (0.04-0.07) )O.S) )0. 71 
l\roc1or 1254 HAS + All 11.34 10.93 0.07 0.05 162.0 218.6 0.03 0.04 
(11.11-11.581 110.62-11.24) (0.05-o.08) (0.03-Q.06) )0.3) )0.4) 
INH-MI\5 + AH 2.01 1.58 0.12 o.u 17.6 
!4.4 o.o~ 0.01 
(1. 73-2.32) (1. 34-1.87) I0.09-o.l5l (0.09-Q.lJ) )1.0) (0.6) 
• Rep<e,...nts the results of two definitive dose-re"""""" experiments with and w1thout each of the metabolic activation syst'.!IIIS 
(uninduced, 1\roclor 154-induced, and isoniazid-induced )INH). l'E'D\X so1ut1on, metabolic oetlvation system IHASI, eyelophosphanude 
(CPI )positive control (4-61 I, oeety1hydrazide IAHI (positive control), and carbon mnodde inactivated HAS la:>-HASI + toucant 
(negative control) controls were pecforaed emeurrent1y with each experiment. Hedian lethal (LC501 and tentogemc (ll:SOI 
c:oneentcations were dete<llined by Litehfield-Milc:oxon probit analyais (231 wi~ 95\ confidence lntecvals 1n parenthe...,s. 
Teratogenic Indices (Til wece calculated by tak11>;1 the ratio of the 96-h LCSO to the 96-h EX:50 (malformatlonl. H1n111U11 
concentrations to inhibit growth IPCIGI were detenuned by the T-test (p<O.OS). 
• nt>leVIn.E:Valuation of the O..Velopoental ToXlcity of Ieonicotin1c Acid fiNAl With FE'll\X. 
'1WM1Irm' 
'llQD 'IWI!IIIG LC50 a:so (N) (N) ,.,/111) ,.,/al) 
l!!2"!.!!!:. 
2 2 
PE'PIX so lutlon 0.6 1.9 
(320) (3191 
()Jinduc:ed-!Wl 0 0 
(80) (801 
Aroclor 1254-MM 0 0 
(80) (801 
liiH-IQS 0 1.3 
(80) (80) 
4.0 or;!/al CP 3.8 7.8 
(801 1771 
3.0 _,/•I AH 1.3 100.0 
(80) (791 
()Jlnduc:ed-!Wl + 4. 0 _,/Ill CP 7.5 21.5~ 
(801 (741 
Aroc1or 1254-MM + 4.0 or;~/111 CP 97.5 100.0 
(80) (2) 
INII-MI\S f. 3.0 111\ltal AH 87.5 100.0 
(801' (70) 
ro-untmUCP.<I-w.s + 3.0 .,;.,1 INA 62.5 100.0 
(801 (30) 
ro-Aroc1or 1254-MM • 3.0 .,;a1 INA 52.5 100.0 
(80) (38) 
a>-INII-IIAS + 3.0 _,;al INA 61.3 100.0 
(80) (31) 
INA 3.16 3.20 1.24 1.28 
(3.04-3.28) (3.08-3.32) (1.16-1.34) (1.19-1. 371 
()Jinduc:ed-~Wl + INA 3.22 3.33 1.51 1.62 
(3.14-3.39) (3.17-3.50) (1.39-1.641 (I. 38-J. 75) 
Aroclor 1254-MM • INA 3.28 3.30 1.57 1.46 
(3. 03-3. 47) (3.15-3.491 (1.43-1. 721 (1 33-I. 71) 
!Nil-liAS f. INA 3.26 3.32 1.44 1.62 
(3.05-3.521 (3.12-3. 53) (1.32-1.59) (1.44-1.821 
a 
'1'1 ICIG 
lor;~/llll) 
l' of LC50J 
2.6 2.5 1.25 1.0 
(39.6) (31.31 
2.1 2.1 1. 35 1.25 
141 91 (37 51 
2.0 2.3 1.0 1.25 
(JO 41 (37.9( 
2.3 2.1 1.25 I. J 
(38.31 (39.21 
A>!pt"esents the results of two definitive dose-response t!llpuiments with and without each of the ..,tabollc activation systems 
(unlnciUCP.<I, Aroc1or 154-lnduc:ed, and ISoniazid-induced (IHH). P'E'1liX solution, metabollc activation system (liAS), cyclophosplu•nde 
(CP) (positive control (4-611, acetylhydrazide (AH) (positive control), and carbon IIDnOXide 1nact1vated MAS (ro-MASI • toucant 
(neqative control! controls were perfor:JII!d concurrently with each experiment. lledlan lethal (l.CSOI and teratogenic (El:SOI 
concentrations were dete .. lned by Litchfleld-WUCOJ<on probit analysis (23) with 95' confidence Intervals 1n porenti"P.ses. 
Teratogenic Indices ('I'll were calculated by taking the ratio of the 96-h l.CSO to the 96-h El:SO lmalformattonl • M1nunum 
concentrations to inhibit growth (ICIGI were detenolned by the '!'-test (p<D.05). 
Table IX. Terata In:iuced 1n ~ by Exposure to Isontazld (INB) , Acetylhydraz1de CAB) , an:i Ison1cotln1c Acld (INA) • 
Treatment 
b 
INB 
INIHWi + INB 
b 
AB 
INIHWi + AB 
d 
INA 
Concentratlon 
a 
(..;J/IDl) 
>0.2 
>0.8 
>1.0 
>0.2 
>0.4 
>0.8 
>0:02 
>0.05 
>0.15 
>0.04 
>0.06 
>0.15 
>1.5 
Terata Induced 
Skeletal Klnklng, Incomplete Mouth Development, Gut MlSCOlllng 
Eye Malformatwns 
Incomplete Heart Development, Pencard1al Edema 
Visceral Edema, Gut Mlsco1hng 
c 
"Cran1ofac1al Defects, Muscular Kinktng " 
Skeletal Klnklng, Eye Malformatlons, Incomplete Mouth Development, 
M1croencephaly 
Gut M1,scoillng, Skeletal Kink1ng 
Abnormal Mouth Oevelopnent 
Eye"_Malformatlons, V1sceral Edema, Abnormal Heart Development, 
Cran1ofac1al Defects 
Gut MlSCOlhng 
Skeletal K1nk1ng, M1croencephaly 
Hydrocephalus, Cran1ofac1al Defects, Bl1ster1ng of the Dorsal Ftn, 
Eye Malformatlons 
Gut M1sco11lng, Cran1ofac1al Defects, Pencard1al Edema 
c 
>1.8 Eye Malformations, Bypognath1a, Muscular, Kinklng 
>3.0 Ophthalm1c Edema, V1sceral Edema, M1croencephaly, Hydrocephalus 
a 
Oef1nes concentrat1on range of teratogen1c1ty. 
b 
Treatments with INB or AH an:i e1ther the un1n:iuced or Aroclor 1254-znduced MAS produced Sl.l!ltlar malformat1ons at the 
g1ven concentrat10ns. 
c 
Term muscular k1nk1ng, caused most likely by abnormal som1te development, 1s used to dtfferentlate from that f1n:i1ng 
termed skeletal klllktng 1n wh1ch the sp1ne (tncludlng the notocord) ts affected. 
d 
Treatments w1th INA an:i any of the HAS produced suuilar malformat1ons at the gtven concentrat1ons. 
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ABSTRACT 
Use of the Frog Embryo Teratogenesis Assay - Xenopus (FETAX) 
and an Exogenous Metabolic Activation System to Evaluate the 
Developmental Toxicity of Diphenylhydantoin. Fort, D.J. and 
Bantle, J.A. (1989). Fundam. Appl. Toxicol. 
The teratogenic potential of d~phenylhydantoin (DPH) 
and hydroxylated metabolites (HPPH) was evaluated with the 
Frog Embryo Teratogenesis Assay- Xenopus (FETAX). Embryos 
of the South African clawed ,frog, Xenopus laevis were 
exposed to DPH and HPPH in two separate static-renewal 
experiments with and without the presence of an exogenous 
metabolic activation system (MAS) for 96 ·hr. Two separate 
dose-response tests were also conducted with DPH and HPPH 
with a MAS modulated by various mixed functional oxidase 
inhibitors (carbon monoxide (CO) (broad spectrum cytochrome 
P-450), cimetidine (mainly cytochrome P-450), and 
ellipticine (cytochrome P-448)] and an epoxide hydrolase 
inhibitor (cyclohexene oxide]. Assessment of the,potential 
teratogenic hazard was based on teratogenic indices [TI=96-
hr LC5Q/96-br EC50 (malformation)], types anq severity of 
malformations, and embryo growth endpoints. Addition of the 
intact MAS to DPH increased the 96-hr LC50 and EC50 
(malformation) fro~ approximately 74.5 and 32.4 mgjL to 
126.4 and 62.9 mgjL, repectively. The TI was reduced 1.2 
fold. Both p-HPPH and m-HPPH were much less developmentally 
toxic than DPH. co and cimetidine inhibition of cytochrome 
94 
P-450 maintained much of the developmental toxicity of DPH, 
whereas ellipticine inhibition of cytochrome P-448 was much 
less effective in maintaining the developmental toxicity of 
DPH. Cyclohexene oxide inhibition of epoxide hydrolase 
markedly increased DPH-induced embryotoxicity decreasing the 
96-hr from approximately 74.5 to 38.6 mgjL. These results 
suggest that unmetabolized DPH and an embryotoxic epoxide 
> > 
intermediate may serve as the te+atogenic species in FETAX. 
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INDEX TERMS 
Xenopus, Metabolic Activation System, FETAX, Mixed 
Functional oxidase, Epoxide Hydrolase, Developmental 
Toxicity, Teratogenicity, Diphenylhydantoin, 5-(4-
hydroxyphenyl)-5-phenylhydantoin, 5-(3-hydroxyphenyl)-5-
phenylhydantoin, Carbon monoxide, Cimetidine, Ellipticine, 
Cyclohexene Oxide. 
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INTRODUCTION 
Demand for routine developmental toxicity hazard 
assessment necessitates the development, validation, and use 
of alternate test systems to traditional mammalian test 
systems (Br~wn, 1987). In vitro test systems, such as the 
Frog Embryo Teratogenesis Assay-Xenopus (FETAX) provide a 
/ ' ' ' 
rapid, cost-,effectt ve method of deterinini~g compounds and 
complex mixtures which may be potential teratoge~ic hazards, 
and offer insight into toxicological- mechanisms-of 
teratogenesis. , FETAX is a 96-hr i whole.:.embryo_ developmental 
' -
toxicity bioassay -employing embryqs of the South African 
- -
clawed frog Xen9pus l·aevis (Dumont et al., 1983). Because 
' Xenopus embryos lack; many metapol~c enzyme systems through 
the first 96 hr of development,, an in vitro metabolic 
activation system (MAS) was developed (Fort et al.~ 1988) 
and evaluated (Fort,et al._, 1989) using Arocior 1254-induced 
rat liver m~~rosomes. Th~ ,developmental toxicity of 
nicotine and a primary metabplite ?Otinine was also 
evaluated using FETAX and MAS (Dawson et al. ,_ 1988) . 
Elucidating possible toxicologica~ mechanisms of 
- , 
teratogenesis in in·'vivo test _.sy~tem7i is difficul-t ·due to 
the complexity of the placental relationship between mother 
and embryo. ~etal'and-maternal 'drug pharmacokinetics and 
' ' 
xenobiotic metabolism also compound the problem as 
exemplified by previous 'studies with the anticonvulsant 
drug, diphenylhydantoin (DPH) (Flint and Brown, 1987). 
Results from in vivo mammalian studies provide evidence for 
97 
DPH as a proteratogen {Harbison, 1978; Martz et al., 1977), 
as well as the ultimate teratogen {McClain and Rohrs, 1985; 
Hansen and Hodes, 1983; Harbison and Becker, 1970). Recent 
in vitro studies with the whole-rat embryo {Bruckner et al., 
1983) and differentiating rat embryo mid-brain and limb 
culture {Flint and Orton, 1984) .seem to indicate that DPH is 
a direct-acting teratogen not requiring exogenous 
bioactivation. Probable metabolic pathways for DPH {see 
Fig. 7) have been studied by a number_of investigators 
{Barcellona et al., 1987; Glazko, 1987; Martz et al., 1977; 
Chang et al., 1970; Maynert, 1960; Butler, 1957). Steps 
involving the formation and detoxification of highly 
embryotoxic arene oxide intermediates by cytochrome P-450 
{P-450) and epoxide hyd~olase or spontaneous isomerization 
appear to be the most important {Martz et al., 1977; Jerina 
and Daly, 1974). Meta and para isomers of 5-
{hydroxyphenyl)-5-phenylhydantoin {HPPH) and 5-{3,4-
dihydroxy-1,5-cyclohexadien-1-yl)-5-phenylhydantoin 
{dihydrodiol) are generated via spontaneous isomerization. or 
by enzymatic inactivation by epoxide hydrolase (Barcellona 
et al., 19i37Y. · Pantarotto et al. (1982) further . 
hypothesized that an additional arene oxide intermediate may 
be generated by MFO oxidation of the major metabolite, HPPH. 
In this report we evaluate the developmental toxicity of 
DPH and HPPH using an exogenous MAS and various inhibitors 
of the microsomal mixed-functional oxidase system (MFO) and 
epoxide hydrolase. The results presented show the utility 
98 
of FETAX as a screen for developmental toxicants and further 
demonstrate the value of FETAX in elucidating potential 
toxicological mechanisms of teratogenesis. 
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METHODS 
Microsome Preparation 
Aroclor 1254-induced rat liver microsomes were prepared 
as described previously (Fort et al., 1988). Five days 
prior to microsome preparation, adult male Sprague-Dawley CD 
strain rats (125-200 g) were injected with 500 mgjKg Aroclor 
1254 in corn oil (Freireich, 1977). Following cervical 
dislocation, the liver was perfused with 0.02 M Tris-HCl 
buffer containing 1.15% KCl, pH 7.5, and subsequently 
homogenized in 1.15% KCl-0.05 M Tris-HCl containing 0.5% 
bovine serum albumin, pH 7.5. Homogenate was then 
successively centrifuged at 600 and 9,000 x g. Purification 
of the crude S-9 supernatant was achieved by 
ultracentrifugation at 120,000 x g. The microsomal pellet 
was resuspended in 0.05 M Tris-HCl, pH 7.5, put into 2 ml 
aliquots, and immediately frozen in liquid nitrogen (Dent et 
al., 1981). Protein content was determined by the method of 
Bradford (1976). P-450 activity was inferred by the 
measurement of formaldehyde generated from the N-
demethylation of aminopyrine (APD) (Nash, 1955) under 
stand~rd assay conditions previously established by Lucier 
et al. (1971). Specific aliquots were pretreated with 
microsomal enzyme inhibitors (Bantle and Dawson, 1987; Brown 
et al., 1986): carbon monoxide (CO-MAS) [broad spectrum P-
450 inhibitor], cimetidine (mainly P-450 inhibitor), 
ellipticine (P-448 inhibitor), and cyclohexene oxide 
(Guenthner, 1986; Oesch et al., 1971) (epoxide hydrolase 
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inhibitor) to modulate metabolic activity. Inhibition by co 
was obtained by chemically reducing designated aliquots with 
dithionite and pretreating with co for 3 min. Cimetidine, 
ellipticine, and cyclohexene oxide were added directly to 
the appropr,iate microsome aliquots. 
Animal Care and Breeding 
Xenopus adult care, breeding, and embryo collection 
were performed according to Dawson and Bantle (1987). 
Assay Protocol 
For unactivated tests (no MAS), groups of 20 embryos 
were placed in 60 mm covered plastic Petri dishes with 
varying concentrations of DPH (Sigma Chemical Co., St. 
Louis, MO), p-HPPH, and m-HPPH (Aldrich Chemical Co., 
Milwaukee, WI) . Stock solutions were prepared by dissolving 
in 1% (vjv) DMSO diluted in FETAX solution, a reconstituted 
water media suitable for culturing Xenopus embryos (Dawson 
and Bantle, 1987). FETAX solution contains 625 mg NaCl, 96 
mg NaHC03 , 75 mg Mgso4 , 60 mg CaS042 H2o, 30 mg KCl, and 15 
mg cac12 per 1 of solution, pH 7.9. DMSO not in excess of 1% 
(vjv) was previously found to have no significant effect on 
microsomal APD activity, as well as embryo growth and 
development (Fort et al., 1989). The DPH stock solution 
concentration was confirmed spectrophotometrically at 35 nm 
(Sunshine, 1981) • For each compound 8 to 16 concentrations 
were tested in duplicate. DPH and HPPH concentrations 
ranged from 20 to 100 mgjL and 80 to 150 mg/L, respectively. 
For tests with DPH and the cyclohexene oxide-MAS, DPH 
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concentrations ranged from 5 to 75 mgjL. Four separate 
dishes of 20 embryos were exposed to FETAX solution 
(designated FETAX solution controls). Forty embryos, 20 per 
dish, were exposed to 1% DMSO and,served as solvent 
controls. Each treatment conta.ined a total of 8 ml of 
solution. 
Experiments conducted with-MAS and inhibited MAS were 
performed in duplicate .with 20 embryos per dish. 
Preliminary experiments were conducted.to determine the 
maximum concentration of inhibitor which did not 
significantly affect embryo develcrpment. Each activated 
treatment received 0.04 U APD.a:ctivity (expressed as uM 
formaldehyde generated/min), an NADPH generating system, and 
100 U/ml penicillin-100 ugjml streptomycin. The NADPH 
generating system consisted of 3.5 mM glucose-6-phosphate, 
0.31 IU glucose-6-phosphate dehydrogenase, 0.1 mM NADP, and 
0.7 uM NADPH. Each dish- received no more than 60 ugjml 
microsomal protein ·(Fort et al., 1988). Controls for FETAX 
solution, DMSO, MAS, inhibitor-MAS, MAS + DMSO, inhibitor-
MAS + DMSO, cyclophosphamide (CP) [FETAX reference 
proteratogen] (Dawson et al., 1988), and unactivated 
toxicant were also run with each individual test. 
Two separate definitive tests were conducted following 
establishment of concentration ranges in preliminary 
experiments for each particular treatment. For experiments 
performed with metabolically activated HPPH and HPPH plus 
cyclohexene oxide-MAS, one range and one definitive test 
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were run. The pH of all stock solutions was maintained 
between 8.2 and 8.5. Embryos were cultured at 23 + 1°c 
throughout the test. All solutions were removed every 24 hr 
of the 4-d test and fresh solutions were added. Dead 
embryos were removed when solutions were cnnaged. Following 
96 hr of exposure, survivin~ embryos were fixed in 0.7% 
formalin, pH 7.0. The number of live-malformed embryos and 
the stage of development (Nieuwkoop and Faber, 1975) was 
ascertained us1ng a dissecting microscope., 
Data Analysis 
Litchfield~Wilcoxon probit analysis (Tallarida and 
-Murray, 1980) was used to determine the 96-hr median lethal 
concentration (96-hr LCSO), the 96-hr ECSO, the 
concentration inducing gross ~erata in so percent of the 
surviving larvae, and their r~spective 95 percent confidence 
limits. Compariso~ of dose-response data was performed by 
the method of Sprague and Fogels (1977). A Teratogenic 
Index (TI) which has-proven ~seful in assessing teratogenic 
hazard (Dumont et al., 1983; Courchesne and Bantle, 1985; 
Dawson and Bantle, 1987; Fort et al., 1988; Dawson et al., 
1988; Dawson et al;, '1989) was det~rmined' by the ratio of 
the 96-hr LCSO to the 96-hr ECSO (malformation). Head-tail 
length was measured-as an indicator of embryo growth using 
' Sigma Scan digitizing software (Jandel Scientific, Corte 
Madera, CA) and an _IBM-AT equivalent personal computer. 
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Results and Discussion 
Control Data 
Maximum non-developmentally toxic concentrations of 
cimetidine, ellipticine, and cyclohexene oxide determined by 
preliminary dose-response experiments were 2.4, 0.04, and 
0.1 mM, respectively (Dunnett's test). These concentrations 
have been pr~viously. shown to inhibit P-450, P-448 (Brown et 
al., 1986), and epoxide hydrolase activity (Oesch et al., 
1971). Marked reduction in the developmental toxicity of 
bioactivated CP (FETAX reference proteratogen) by co- and 
cimetidine-MAS indicates that these concentrations were 
adequate to inactivate P-450 activity. 'The ellipticine-MAS 
failed to reduce the ·developmental toxicity of bioactivated 
CP. These results are consistent with the concept that a 
phenobarbital-inducible P-450 .. isozyme is res~onsible for the 
conversion of CP to an ultimately teratogenic metabolite(s) 
in the rat (Hales and Jain, 1980b; Hales, 1981; Greenaway et 
al., 1982). In addition, neither B-naphthoflavone (Hales 
and Jain, l980b; Hales, 1981) nor 3-methylcholanthrene 
(Greenaway et al., 1982) (P-448-type inducers] had an effect 
on the hepatic bioactivation of CP in vivo or in vitro. 
Control data for experiments performed with DPH, DPH and 
MAS; HPPH, HPPH and MAS, and HPPH and cyclohexene oxide-MAS; 
as well as DPH and selectively inhibited MAS are presented 
in Tables X-XII, respectively. 
Developmental Toxicity of DPH 
Results of tests conducted with DPH and DPH with'MAS 
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are presented in Table XIII. The 96-hr LC50, 96-hr EC50 
(malformation), and TI values were 77.9 and 71.0 mgjL, 33.0 
and 31.8 mgjL, and 2;4 and 2.2, respectively-. These results 
are consistent with those obtained by Sabourin and Faulk 
(1987) with Xenopus (TI = 1.5-2.6). Exogenous 
bioinactivation significantly (P=0.05) increased the 96-hr, 
LC50 of DPH at least 1.8-fold to 122.1 and 130.6 mgjL. 
Addition of the MAS significantly (P=0.05) increased the 96-
hr EC50 (malformation) to 62.9 and 75.4 ~g/L (at least 2.4-
fold). Bioinactivation produced TI values of 1.9 and 1.8. 
Concentration ranges and teratologic~! effects of DPH on 
Xenopus embryo development are presentee in Table XIV, as 
well as illustrated in Fig. 7. The effect of DPH and 
bioactivated DPH on 96-hr embryo growth is presented in 
Figure 8. Inclusion of MAS with DPH,reduced some growth 
inhibiting effects caused by DPH exposure. 
Developmental Toxicity of HPPH 
Table XIII shows the results of tests performed with 
HPPH, HPPH and intact MAS, an~ HPPH and cyclohexene oxide-
MAS. None of the embryos exposed to either p-HPPH or m-HPPH 
with or without the addition of the intact MAS or' 
cyclohexene oxide-MAS died at maximum soluble concentrations 
in 1% (vjv) DMSO (150 mg/L). At a concentration of 150 mg/L 
p-HPPH and m-HPPH induced malformation rates of 17.5% and 
16.3% (N=160 for both), respectively. Thus, 96-hr LC50 and 
EC50 (malformation) for all three treatments is expressed as 
>150.0 mgjL. Types of terata and appropriate concentration 
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ranges are presented in Table XIV. The effect of HPPH on 
96-hr Xenopus embryo growth is shown in Fig. 8. Neither 
isomer had a pronounced effect on embryo growth with or 
without MAS. 
Effect of MFO and Epoxide H¥drolase Inhibitors on DPH 
Teratogenicity 
Results from tests conducted with co-, cimetidine-, 
ellipticine-, and cyclohexene oxide-MAS and DPH are 
presented in Table XIII. The 96-hr LC50, 96-hr EC50 
(malformation), and TI values for embryos exposed to CO-MAS 
and DPH were 69.3 and 68.8 mgjL, 30.6 and 33.7 mgjL, and 2.3 
and 2.0, respectively. The 96-hr LC50 of cimetidine-MAS and 
DPH treatment was-83.7 and 78.8 mgjL while the 96-hr EC50 
(malformation) w~s .36.0 and 41.8 mgjL. The TI values for 
both trials were 2.3 and 1.9, respectively. The 96-hr LC50 
and EC50 (malformation) values for both the CO-MAS and 
cimetidine-MAS plus DPH treatments were not significantly 
different fro~ values for DPH alone, but were significantly 
different from the .DPH and intact-MAS treatment (P=0.05 for 
both). Exposure to the ellipticine-MAS and DPH resulted in 
a 96-hr LC50 of 98.6 and 95.7 mg/L. The 96-hr EC50 
(malformation) for the same treatment was 59.2 and 53.4 
mg/L, yielding TI values of 1.7 and 1.8. Ellipticine-MAS 
and DPH 96-hr LC50 and EC50 (malformation) values were not 
significantly different from the DPH plus the intact-MAS 
treatment. These endpoints were, however, significantly 
different from those of DPH alone (P=0.05 for both). The 
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96-hr LC50 for cyclohexene oxide-MAS and DPH was 31.5 and 
45.6 mgjL. The 96-hr EC50 (malformation) and TI values were 
24.7 and 39.7 mg/L, and 1.3 and 1.1, respectively. The 
median lethal concentration of the cyclohexene oxide-MAS and 
DPH treatment was significantly different from that of DPH 
alone, but not significantly different from intact-MAS and 
DPH treatment (P=0.05 for both). The 96-hr median 
teratogenic concentration was significantly different from 
the DPH and intact-MAS treatment; however, it was not 
significantly different from DPH alone (P=0.05-for both). 
The effects of DPH and modulation of MAS activity by each 
specific inhibitor on Xenopus e~ryo development and growth 
are presented in Table XIV and Figure 9, respectively. co-
MAS, cimetidine-MAS, arid cyclohexene oxide-MAS and DPH 
caused a slightly great~r reduction in growth than was 
observed by DPH alone. However, embryos exposed to 
ellipticine-MAS and DPH showed less growth reduction than 
those exposed to D~H alone. 
The potential teratogenic hazard of compounds tested 
with FETAX are based on Teratogenic Index (TI) values, 
embryo growth, and the type~ and severity of induced 
anomalies. Typically, TI values <1.5 indicate low 
teratogenic potential since there is little or no separation 
between concentrations that cause malformation, but cause no 
embryolethal effects; and concentrations which are 
embryolethal. Greater TI values signify a larger separation 
between the two aforementioned responses and thus, a greater 
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possibility of embryos being malformed in the absence of 
·significant embryolethality. Because calculation of an 
adult to developmental (A/D) ratio is not practicable with 
FETAX, types and severity of induced malformations must also 
be considered for compounds with TI values <1.5 which 
produce severy deformaties in major organ systems. To 
assess the utility of the TI we are presently establishing a 
large data base with FETAX. Several conclusions,about DPH-
induced teratogenesis in vitro may be drawn from the results 
of this study. First, DPH seems to .be at least partially 
detoxified by MAS as evidenced by the increase in the 96-hr 
LC50 and EC50 (malformation), ~swell as the reduction in 
TI. Inhibition of MAS with known inhibitors of P-450 
prevented the loss.of ~uch of the developmental toxicity of 
unactivated DPH as:indicated by the higher TI values for the 
co- and cimetidine-inhibited MAS and DPH treatments compared 
to bioactivated DPH.· Also, similarities between terata 
observed with the P-450-inhibited MAS and DPH to DPH itself 
(see Table XIV) and the marked inhibition of embryo growth 
in these treatments seem to suggest that unmetabolized DPH 
could partici~qte in DPH-induced teratogenesis. 
Similar results were obtained in mammalian studies both 
in vivo and in vitro. Harbison and Becker (1970) found that 
pretreatment of Swiss-Webster mice with phenobarbitone 
significantly,decreased the teratogenicity of DPH supposedly 
due to enhanced metabolism. By lowering the basal drug 
metabolic rate via dietary modulation in Swiss-Webster mice, 
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McClain and Rohrs (1985) showed that the incidence of DPH 
related abnormalities was increased. Similar results have 
also been reported in different strains of mice with 
specific interstrain variablity in metabolic capacity 
(Hansen and Hodes, 1983). Inhibition of P-448 activity by 
ellipticine has less effect on the developmental toxicity of 
DPH suggesting that, metabolism may be mainly P-450 mediated 
' ' ' 
in FETAX. Barcellcina et al. (1987) drew similar conclusions 
using primipara Swiss CD-1 mice in in vivo developmental 
toxicity tests. However, Brown et al. (1986) found 
ellipticine-inhibition of P-448 to increase the 
developmental toxicity of DPH in the differentiating rat 
limb mesenchymaL.cell culture assay.· This discrepancy may 
be the result of differences ,in pathways utilized in 
xenobiotic metabolism by various cell lines and 
bioactivation systems. 
Second, the primary metabolites (HPPH) of DPH were not 
as developmentally toxic to Xenopus at soluble levels as DPH 
itself. These results would also seem to support .unaltered 
DPH or the epoxide intermediate as the most important 
teratogenic species. Harbison and Becker (1974) report 
similar results in swiss Webster mice ·in· which 87.5 mgjKg 
DPH induced 85% orofacial anomalies whereas equimolar doses 
of ~he·metabolite~ diphenylhydantoic acid, p-HPPH, and 
aminodiphenylacetic acid did not produce a significant 
incidence of these defects. However, conflicting results 
were obtained in vitro in the differentiating rat embryo 
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limb cell assay in which DPH was found to be nearly 
equitoxic with both isomers of HPPH (Brown et al., 1986). 
Third, potentiation of DPH embryotoxicity caused by 
epoxide hydrolase inhibition with cyclohexene oxide 
implicates the"possibility of an embryotoxic arene oxide 
intermediate. The 1.9-fold decrease in the 96-hr LC50 of 
DPH, as well as the reduction in TI with the epoxide 
hydrolase-inhibited MAS indicates that the arene oxide is 
significantly more embryolethal than DPH itself in FETAX. 
However, the severity of malformations induced and the 
significant reduction in embryo growth suggests that the 
epoxide intermediate poses a teratogenic threat to the 
surviving embryos. Thus, the role epoxide intermediates 
play in the developmental toxicity of DPH appears to be of 
major importance which is consistent with several in vivo 
findings (Martz et al., 1977; Blake and Martz, 1980; Hansen 
and Hodes, 1983; Barcellona et al., 1987). Brown et al. 
(1986), however, found that trichloropropene oxide (TCPO), a 
potent inhibitor of epoxide hydrolase, treatment of cultured 
differentiating rat limb cells exposed to DPH had no effect, 
thus arguing against arene oxide formation being responsible 
for the toxicity observed. Since we were not able to use 
TCPO because of the lack of availability from commercial 
vendors, no direct comparison can be made. We are presently 
unable to explain the descrepancy in results. In addition, 
the concentrations of TCPO used in the Brown et al. (1986) 
study may not have provided sufficient inhibition of epoxide 
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hydrolase. Because no embryolethal and limited (<20%) 
teratogenic effects were generated by exposing Xenopus 
embryos to HPPH a~d the intact or epoxide hydrolase-
inhibited MAS, _a s~cond route of arene oxide formation -from 
HPPH does not see~ t9 play a role in DPH teratogenesis in 
FETAX (see Fig. 7) •. 
Unactivated DPH induced malformations of ~he 
craniofacial region, heart and brain in Xenopus. Similar 
malformations were.observed in the inhibited•MAS and DPH 
treatments. Em}?ryos exposed . ,to DPH and. intact MAS also 
exhibited bo~y ~lexure and ske+etal malformations. Skeletal 
kinking observed in Xenopus embryos ~ay bear some 
relationship to skelet.al limb ario!Ualies observed in mammals 
(Dawson and Bantle, 1987). Although body flexure 
malformations and. sk,elet,al J:cinking were observed in a small 
percentage (<20% at.150'mg/L) ·of HPPH treated embryos, they 
were the primary anomalies obs~rved with HPPH. Skeletal 
defects were observed in the epoxide hydrolase-i~hibited MAS 
' ' 
and DPH treatment. The occurrence of these malformations in 
the DPH and intact MAS trea~m~nts further suggests that DPH 
metabolism· was .taking place in the -·MAs supplemented ·. 
treatments. Similarity in the types of malformations 
induced by DPH with and without Mis'may be due in part to 
residual unme~~bolized DPH. Several of the malformations 
caused by DPH in Xenopus are similar to those found in 
mammals including humans. Single in]ections of DPH on days 
10-12, 14 and 15 in Swiss-Webster mice produced open eye, 
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ectrodactyly, cleft lip and palate, hydronephrosis, internal 
hydrocephalus, and skeletal defects (Harbison and Becker, 
1969). Cases of cleft palate (McClain and Rohrs, 1985) and 
orofacial defects (Harbison and Becker, 1974) have also been 
reported in Swiss-Webster and A/J mice (Massey, 1966). Open 
eyes, cleft palate, and v~rious limb defects were observed 
in New Zealand white-rabbits exposed to DPH (McClain and 
Langhoff, 1980)_ Bruckner et al. (1983) found cranial 
defects, abnormal body curvature, and craniofacial defects 
in cultured whole-ICR mice exposed to DPH. Similar 
malformations have'been observed in,the rat, however, it 
appears less suceptible than the,mouse to the teratogenic 
action of DPH. DPH-induced in utero toxicity and fetal 
growth inhibition are similar in both species, however 
(Harbison and Becker, 1972) .. Since DPH is extensively p-
hydroxylated in the rat (Butler, 1957), Harbison and Becker 
(1972) suggest that sensitivity may be due to species 
variation in the temporal arrangement of development on the 
genetic regulation of morphogenesis. Exposure to serum from 
Fischer 344 rats chronically exposed to phenytoin produced 
severe cardiovascular defects in cultured rat embryos 
• ' < 
(Clapper et al., 19~6). Abnormalities (commonly referred to 
as fetal hydantoin syndrome) including craniofacial defects, 
nail and digital· hypoplasia, and pr~natal-onset growth 
deficiency have been found in children born,to epileptic 
mothers treated with hydantoin anticonvulsants (Hanson and 
smith, 1975) • 
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Evaluating possible interactions between DPH or HPPH, 
DMSO, and the inhibitors was virtually impossible in this 
study due to the complexity of the exogenous MAS. However, 
we are presently investigating the effect of solvent 
interactions on the developmental toxicity of a variety of 
compounds with FETAX. 
! 
Since FETAX is an in vitro system providing abiotic 
exposure of toxicants including metabolites, establishment 
of precise toxicological mechanisms may be subject to 
simplification. The complex pharmacological and 
toxicological effects of DPH are not as apparent as with 
compounds such as CP. However, in cases where mechanistic 
descrepancies occur in vivo, in vitro systems may help 
provide information. Results of FETAX tests with DPH, the 
primary metabolite HPPH, and an exogenous metabolic 
activation system modulated by various microsomal inhibitors 
suggest that DPH-induced teratogenesis may be the result of 
both unmetabolized DPH and a,highly embryotoxic arene oxide 
intermediate. This study further demonstrates the capacity 
of FETAX to determine differences in the teratogenic 
potential of a toxicant due to metabolism and ellucidate 
possible mechanisms of teratogenesis in vitro. Such results 
are indicative of the versatility of FETAX in the rapid 
screening of developmental toxicants. 
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Table X. Control Data for Experiments Performed with Diphenylhydantoin. (DPH) and DPH with 
the Metabolic Act1vat1on System (MAS). 
Treatment N t Dead t Malformed 
(%) (%) 
FETAX SOIDTICN 320 2 14 
(0. 6) . (4~4) 
b 
r.MSO- 160 ' 2 4 
(1.3) (2.6) 
MAS 80 1 3 
(1.3) (3.8) 
MAS + r.MSO 80 2 5 
(2.5) (6.4) ----
- c 
80 
(100.0) 
4.0 ~/ML CP- 80 
a 
Expressed as percent of mean FETAX solution control lengtii :!: SE.-
,b 
1% (v/v). " 
c 
Cyclophosphamid~. 
a 
Growth 
100.0 ± 1.1 
99.4 .:!;_2.2 
98.2 .± 1.6 
96.8 .± 1. 7 
Table XI. Control Data for Experunents Performed with Hydroxylated Metabolites of Diphenylhydantoin (HPPH), HPPH 
and the Metabo,lic Activatlon System (MAS), arrl HPPH and the Cyclohexene OXlde-Inhibited MAS. 
Treatment 
rerAX .so.wrrCN 
c 
IJoiSO-
MAS 
CYCIDHEXENE OXIDE-MAS 
d 
4.0 MG/ML CP- + 
MAS---
a 
a 
[Inhibitor ] 
(WI) 
0.1 
N 
480 
240 
80 
80 
80 
80 
f Dead 
(%) 
1 
(0.2) 
1 
(0. 4) 
2 
(2.5) 
2 
(2.5) 
0 
(0) 
0 
(0) 
80 
(100.0) 
f Malformed 
(%) 
15 
(3.2) 
7 
(2.9) 
1 
(1.3) 
2 
(2.6) 
3 
(3.8) 
7 
(8.8) 
b 
Growth 
100.0 :!: 0.8 
98.5 :t 1.5 
96.7 ± 1.3. 
97.6 ± 1.0 
95.6 ± 2.2 
95.3 ± 2.3 
Represents concentrat1on 1n m1crosamal preparat1on. No Observable Effect Concentrat1on (malformatlon) 
as determ1ned by Dunnett's test. 
b 
Expressed as percent of mean F~ solution control length ± SE. 
c 
1% (v/v). 
d 
Cyclophosphamlde. 
Table~ Control Data for Experiments Performed with Diphenylhydantoin (DPH) and Selectively Inhibited 
B!oactivation System (HAS). 
Treatment 
FETAX SOWTICII 
-----
c 
DISO-
CIMETIDINE-MAS 
EILIPTICINE-MAS 
CYCUl!EXEllE OXIDE-MAS 
c 
ro-HAS +. DISO-
------
CIHETIDINE-MAS 
c 
.:!:. DISO-
EILIPTICINE-MAS 
c 
+ [f!SQ-
a 
4.0 I'Ki/ML CP- + 
ro-HAS-- -
a 
4.0 I'K>/ML CP- + 
ffii'E:rloiNE-=M:As-
a 
4.0 I'K>/ML CP- + 
ELExffiCniE-MAS 
a 
4.0 I'K>/ML CP- + 
crcli.iiEXENEoxYDE-
HAS 
a 
a 
[Inhibitor I 
(ntl) 
2.4 
0.04 
0.1 
2.4 
0.04 
0.1 
2.4 
0.,04 
0.1 
N 
640 
320 
80 
80 
80 
80 
80 
80 
80 
80 
80 
80 
80 
80 
Dead 
I'! 
2 
(0.3) 
2 
(0.6) 
1 
(1.3) 
1 
(1.3) 
0 
(0) 
0 
(0) 
2 
(2.5) 
1 
(1.3) 
1 
(1.3) 
0 
(0) 
3 
(3.8) 
10 
(12.5) 
77 
(96.3) 
79 
(98. 7) 
Malformed 
I'! 
15 
(2.4) 
9 
(2.8) 
4 
(5.1) 
2 
(2.6) 
3 
(3.8) 
3 
(3.8) 
3 
(3.8) 
4 
(5.1) 
4 
(5.1) 
6 
(7.5) 
6 
(7.8) 
18 
(25. 7) 
3 
(100.0) 
1 
(100.0) 
Represents con<"entration in microsanal preparation. No Observable Effect Concentration 
(malformation) as determined by Dunnett's test. 
b 
Expressed as percent of mean F~ solution control length ! SE. 
c 
1\ (v/v). 
d 
Cyclopho~phamlde. 
Growth 
100.0 ± o. 7 
99.1 ± 0.9 
98.9 ± 1.0 
97.6 :!: 0.8 
97.9 ± 0.9 
97.8 :!: 0.9 
97.5:!: 0.7 
96.7 ± 0.7 
97.5 + 1.6 
94.0 :!: 0.8 
95.0 ± 3.1 
92.8 :!: 1.0 
82.5 :!: 4.2 
41.2 
TableXII[.Effect of Exogenous Bioactivation System (MAS) on the Developnental Toxicity of Diphenylhydantoin (DPII) 
and Primary Hetaboli tes (HPPII) • 
a 
Tl"eal:lnent [Inhibitor I Tdal Unactivated MAS 
(II'H) 
b b c b b c 
96 h u:so 96 h tx:50 TI 96 h U:50 96 h tx:50 TI 
(mg/J.) (mg/L) (mg/L) (mg/L) 
d 
DPII 1 77.9 33.0 2.4 122.1 62.9 1.9 
(70.9-85. 7) (28.6-38.1) (90.2-165.2) (52.6-75.3) 
d d 
2 71.0 31.8 2.2 130.6 75.4 1.8 
(62.4-80.9) (27 .9-36.4) (114.4-149.1) (66.0-86.1) 
e e ef ef 
p-HPPH >150.0 >150.0 >150.0 >150.0 
e e eg eg 
2 >150.0 >150.0 >150.0 >150.0 
e e ef de 
aHIPPII >150.0 >150.0 >150.0 >150.0 
e e eg eg 
2 >150.0 >150.0 >150.0 >150.0 
hi hi 
CD-MAS !. DPII 69.3 30.6 2.3 
(60. 5-79. 3) (26.5-35.3) 
hi hi 
2 68.8 33.7 2.0 
(60.8-77.9) (27.5-41.2) 
hi hi 
CIMETIDINE-MIIS+DPII 2.4 83.7 36.0 2.3 
(12.4-96.8) (31.3-41.3) 
hi hi 
2 78.8 41.8 1.9 
(68. 7-90.4) (37.0-47.2) 
d] dj 
ELLIPTICINE-HAS+DPH 0.04 98.6 59.2 1.7 
(93.3-104.2) (54. 7-64.0) 
dj dj 
2 95.7 53.4 1.8 
(87.9-104.2) (49.4-57.9) 
di hi 
CYCI.aiElCDlE OXIDB-HAS 1 31.5 24.7 1.3 
+DPII 0.1 (25.0-39.6) (18.9-32.4) 
di hi 
2 45.6 39.7 1.1 
(41. 7-49.9) (34.4-45.9) 
a 
Represents concentration in microsomal preparation. No Observable Effect Concentration 
(malformation) as determined by Dunnett's test. 
b 
Determined by Litchfield-l'illcoxon probit analysis (Tallarida and Murray, 1980) with 95' confidence 
tnterval In parenthesis. 
c 
96-hr U:S0/96-hr EC50 (malformation). 
d 
Stgntftcantly different from DPH at P-0.05. 
L1m1t of solubility in n (v/v) IHiO. 
f 
Performed with standard MAS. Summarization of results from two definitive experiments. 
g 
Performed wtth cyclohexene oxtde-HAS. Summarization of results from two definitive 
ex!"'riments. 
h 
Not significantly different from DPR at P=O.OS. 
1 
Stgniflcantly different from DPR and the MAS at P-0.05. 
J 
Not stgntficantly different from DPH and the MAS at P=O.OS. 
Table~.Te~ata Iniuced in~ by exposu~e to DPH and HPPR. 
neabnent 
DPH 
· Co!lcentration 
a 
(mg/L) 
>20 
Terata Induced 
gut miscoiling, perica~dial edema and craniofacial defects / 
>40 mic~oencephaly, niic~oophtllalmia and inconplete <mouth development 
DPH +MilS 
---
c 
HPPR-
CD-MAS + DPH 
-----
CIM!:l'IDINE-Ml\S + DPR 
ELLIPl'ICINE-fV\5 + DPH 
CYCILtiEXENE OXIDE-MilS 
+ DPH 
a 
b 
>60 heart miscoiling (tubular heart) and-muscular- kinking 
>33 
>66 
gut miscoiling and hypognathia 
b 
muscular kinking 
>100 ophthalmic edema, microophthalmia, craniofacial defects, 
>100 
>20 
>50 
>80 
>20 
>40 
>70 
>50 
>70 
>100 
>5 
>10 
>20 
>50 
skeletal kinking and lateral body flexu~e 
- b 
muscular kinking and lateral body flexure 
gut miscoiling; mouth anomalies and craniofacial defects 
pericardia! edema and muscular kinking 
b 
heart miscoiling and muscular kinking 
gut miscoiling . 
. ' 
pericardia! edema, mic~oophthalmia and craniofacial defects 
-b 
muscular ,and skeletal kinking, microencephaly, mouth defects 
gut miscoiling 
microphthalmia, skeletal kinking and body flexure abno~malities 
~hthalmic edema and microencephaly 
gut miscoiling 
severe skin blistering 
b 
skeletal and mu~cular kinking , craniofacial defects, pericardia! 
edema and microophthalmia 
microencephaly and hyd~ocephalus 
Define~ concent~ation ~ange for teratogenicity. 
b 
Te~m muscular kinking, caused most 'likely by abno~mal somite devel~nt, is 
used to differentiate f~om that finding termed skeletal kinking in which the spine 
(including the notoco~d) is affected. 
Treatments with IIPPII and 111\S or cyclohexenE' oxide-MI\S p~oduced similar malformations 
at the given concentrations. 
FIGURE LEGEND 
FIGURE 6 - Probable route of diphenylhydantoin metabolism 
in mammals. 
FIGURE 7 - Malformations and growth reduction caused by 96-
hr exposure to diphenylhydantoin (DPH). FETAX solution 
control embryo (top), embryo exposed to 50 mg/L DPH alone 
(middle), and embryo exposed to 100 mg/L DPH with the MAS 
(bottom). 
FIGURE 8 - Represen~ative growth curves, presented as the 
percent of the mean' FETAX solution controls + SE, for 
' ' 
Xenopus embryos exposed to diphenylhydantoin (DPH) (----), 
DPH with MAS (----), 5- (p-hydroxyphenyl) -5-phenylhydantoin 
(----} and 5- (m-hydroxyphenyl) -5-phenylhydantoin (-- -) 
for 96 hr. 
FIGURE 9 - Representative growth curves, presented as the 
percent of, the mean FETAX solution control + SE, for Xenopus 
embryos exposed to diphenylhydantoin (DPH) (-- -), DPH and 
carbon monoxide-inhibited MAS (----), DPH and cimetidine-
inhibited MAS (-----), DPH and ellipticine-inhibited MAS 
(·- -: -) and DPH and cyclohexene oxide-inhibited MAS (--) for 
96 hr. 
127 
00 
H~><ro J.-NH 
0 
1010 5 5 Q,pnenylhydan 
1DPH1 
HN 
J--NH 
0 lolle.-.ao.en l yiJ 5 (3 4 Dltlyaroxy 1 5 cy~arnyarodiOIJ 5 pn~nylnyaamom 
~';so"" -· 
~ 
OH 
od 
~ J.-NH 
0 
nenyiJ 5 IP Hydroxyp -HPPH) 
5 phenylnyaantorn IP 
+ 
HO 
ob 
~ J.-NH 
0 r.~nyl, 
5 \ffi Hydro~~~ un HPPH) 5 pllenytnyddnt 
Figure 6 
DETOXIFICATION 
-~ EPOXIDE 
/ HYDROLASE 
&lOR 
ISOMERIZATION 

t-ttrl t---r-t 
It i 
It i 
It i 
rr rr 
t / 
I 
j i 
i + t~ + 1 ~ 
,1' 
I 
~-!.:' 
i 
I 
i 
I 
0 
0 
C\2 
~~~~~--~~~~~--~~~ 0 
0 
~ 
0 
0 
0 
m 
0 
c:o 
0 
r-
10H1NOJ L.!IO% 
0 
co 
0 
l() 
I 
I 
I 
I 
I 
I 
I 
1:-i J7-i I ;:> 
,/·· / . 
..-..".! .,.( I ( U .--
. I .A-·--~ 1-rhH'--·--· ~ 
. ~ I I c~~' ~ 
. J/.7 l ~>-~ .. / I 
. K"" l+.f'H c ~·~~ 
: I I · 
~ y1 + 
.J rL ~ / / _./ ' 
. ..--·· 
....( ~ .. 
0 
0 
~ 
0 
m 
0 
co 
10HlNOJ jQ% 
0 
1.0 
0 
0 
C\2 
0 
CHAPTER V 
CONCLUSIONS 
The primary objective of this research project was to 
combine the evaluation of the metabolic activation system 
with creative applications of the system. In an ef.fort to 
validate the Aroclor 1254~induced metabolic .activation 
system on a preliminary basis, the devel9pmental toxicity of 
four compounds thought to be modulated by cytochrome P-450-
mediated metabolism and one compound unaffected by the P-450 
system were tested. With the inclusion of the exogenous 
metabolic .activation system, FETAX correctly predicted the 
teratogenicity of each compound~ However, without the 
bioactivation system FETAX only correctly predicted the 
developmental toxicity o.f two of the five compounds. Thus, 
by implementing a MAS into the FETAX protocol, the 
predictive value of the assay may be increased by decreasing 
. . ' 
the number of potential fal~e-positive and false-:-negative 
test results. 
The developmental toxicity of two compounds, isoniazid 
and acetylhydrazide, metabolized by Aroclor 1254-repressed 
P-450 isozymes (P-450j) was assessed in an effort to 
evaluate the overall efficacy of Aroclor 1254 induction. 
The Aroclor 1254-induced metabolic activation system had no 
132 
significant effect on the developmental toxicity of either 
compound. However, an isoniazid-induced bioactivation 
' ' 
system significantly altered the developmental toxicity of 
isoniazid producing a more embryolethal, but less 
teratogenic species. Several chemicals have been shown to 
be metabolized by P-450j including, pyrazole, imidizole, 
acetone, trochloroethylene, N-nitrosodimethylamine, and 
ethanol. Thus, Aroclor 12S4-induced' liver microsomes may 
' " 
prove to be counter-productive for_in vitro developmental 
toxicity screening systems in these situations. To increase 
the predictability of the metabolic activation system 
routinely used ~y FETAX, mixtures of microsomes induced by a 
broad-spectrum of P-450 inducing agents are currently being 
' ' ' 
tested. In addition, these results suggest that false-
positive test results ob~ained with isoniazid using several 
in vitro test systems may be th~ result of metabolic 
incompetence. 
To demonstrate the utility and versatility of FETAX and 
the exogenous metabolic activation syst~m, the developmental 
toxicity of diphenylhydantoin was evaluated with a 
bioactivation system modulated by various metabolic 
inhibitors to identify toxicological mechanisms of 
teratogenesis. Result~ suggest that the parent compound and 
a highly embryoto~ic arene oxide intermediate were 
responsible for diphenylhydantoin-induced developmental 
toxicity in FETAX. 
Without the ability to metabolize xenobiotics, it is 
133 
doubtful that in vitro tests, including FETAX, would be 
suitable for screening potential human developmental 
toxicants. Results from this research suggest that FETAX 
may be able to overcome the obstacle of maternal metabolism. 
Since FETAX is an in vitro system, providing abiotic 
exposure of toxicants and metabolites, the pharmacological 
, relationship between the fetal and maternal systems has been 
oversimplified. However, FETAX provides an opportunity to 
compare the developmental toxicity of parent compounds to 
metabolites and possibly generate information concerning 
toxicological mechanisms of teratogenesis. 
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